1
|
Nicolaidou E, Fouseki K, Paparizos V, Kotsafti O, Vasalou V, Daskalakis E, Lakoumentas J, Giannoukos A, Emmanouil G, Kapranou R, Kripouri Z, Papanikou S, Stefanaki I, Tagka A, Gregoriou S, Paparizou E, Stratigos A. A sharp increase in early syphilis cases in a referral hospital in Athens, Greece, 2 years into the COVID-19 pandemic. J Eur Acad Dermatol Venereol 2024. [PMID: 38380596 DOI: 10.1111/jdv.19884] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2023] [Accepted: 02/09/2024] [Indexed: 02/22/2024]
Affiliation(s)
- E Nicolaidou
- 1st Department of Dermatology and Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital, Athens, Greece
| | - K Fouseki
- 1st Department of Dermatology and Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital, Athens, Greece
| | - V Paparizos
- 1st Department of Dermatology and Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital, Athens, Greece
| | - O Kotsafti
- 1st Department of Dermatology and Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital, Athens, Greece
| | - V Vasalou
- 1st Department of Dermatology and Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital, Athens, Greece
| | - E Daskalakis
- 1st Department of Dermatology and Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital, Athens, Greece
| | | | - A Giannoukos
- 1st Department of Dermatology and Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital, Athens, Greece
| | - G Emmanouil
- 1st Department of Dermatology and Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital, Athens, Greece
| | - R Kapranou
- 1st Department of Dermatology and Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital, Athens, Greece
| | - Z Kripouri
- 1st Department of Dermatology and Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital, Athens, Greece
| | - S Papanikou
- Department of Dermatology, National Health System, "A. Sygros" Hospital, Athens, Greece
| | - I Stefanaki
- 1st Department of Dermatology and Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital, Athens, Greece
| | - A Tagka
- 1st Department of Dermatology and Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital, Athens, Greece
| | - S Gregoriou
- 1st Department of Dermatology and Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital, Athens, Greece
| | - E Paparizou
- 1st Department of Dermatology and Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital, Athens, Greece
| | - A Stratigos
- 1st Department of Dermatology and Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital, Athens, Greece
| |
Collapse
|
2
|
Koumourtzis MR, Georgakopoulos I, Lampadaki K, Vaiopoulos A, Marinos L, Platoni K, Mpouhla A, Kypraiou E, Nikolaou V, Tsirigotis P, Kouloulias V, Pappa V, Stratigos A. Low vs. high-dose total skin electron beam therapy for mycosis fungoides: efficacy and safety analysis. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)00644-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
3
|
Papadavid E, Koumourtzis M, Nikolaou V, Lampadaki K, Marinos L, Patsatsi A, Georgiou E, Dalamaga M, Stratigos A. Chlormethine gel is effective for the treatment of skin lesions in patients with early- and late-stage mycosis fungoides in clinical practice. J Eur Acad Dermatol Venereol 2022; 36:1751-1757. [PMID: 35470483 DOI: 10.1111/jdv.18183] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2021] [Accepted: 04/19/2022] [Indexed: 11/26/2022]
Abstract
BACKGROUND Chlormethine gel is a skin-directed therapy used for patients with mycosis fungoides (MF) that showed a favorable risk/benefit profile in a randomized clinical trial. Currently, data on chlormethine gel use in real-world settings are limited. OBJECTIVES To assess safety and efficacy of chlormethine gel treatment in patients treated during daily clinical practice, and investigate associations between response and disease stage, lesion type, mono- or combination therapy, and occurrence of dermatitis. METHODS Clinical data from patients using chlormethine gel from three sites in Greece were analyzed. Efficacy was assessed through modified Severity-Weighted Assessment Tool (mSWAT) scores. Safety assessments included analysis of the occurrence and severity of dermatitis. The Skindex-29 questionnaire was used for quality-of-life assessments. RESULTS Fifty-eight patients were included. The overall response rate (ORR) increased from 37.9% at month 1 to 80.8% at month 9. For 64.2% of patients, response was maintained for at least 4 months (ORR4). At month 3, a higher ORR was seen for patients with patches (69.7%) than patients with plaques/tumors (both 15.2%). A higher ORR4 was observed for patients with early- vs late-stage disease (71.4% vs 36.4%) and patients on mono- vs combination therapy (75% vs 47.6%). Dermatitis was observed in the majority of patients (72.4%), but the presence or severity of dermatitis was not directly correlated with treatment response. Both mSWAT and Skindex-29 scores decreased significantly during treatment, and changes in these scores from baseline to month 6 showed a positive correlation (r = 0.55, P = 0.026). CONCLUSIONS Chlormethine gel was effective for treatment of skin lesions in patients with early- and late-stage MF in clinical practice. Response rates increased over time, indicating that continued treatment with the gel is important. Dermatitis may be managed by reducing the treatment frequency; the occurrence of dermatitis did not affect the response to treatment.
Collapse
Affiliation(s)
- E Papadavid
- 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, "Attikon" University General Hospital, Athens, Greece
| | - M Koumourtzis
- 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, "Attikon" University General Hospital, Athens, Greece
| | - V Nikolaou
- 1st Department of Dermatology and Venereology, National and Kapodistrian University of Athens, University of Athens Medical School, "Andreas Sygros" Hospital for Skin Diseases, Athens, Greece
| | - K Lampadaki
- 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, "Attikon" University General Hospital, Athens, Greece
| | - L Marinos
- Department of Hematopathology, Evangelismos General Hospital, Athens, Greece
| | - A Patsatsi
- 2nd Dermatology Department, Aristotle University, School of Medicine, Papageorgiou General Hospital, Thessaloniki, Greece
| | - E Georgiou
- 2nd Dermatology Department, Aristotle University, School of Medicine, Papageorgiou General Hospital, Thessaloniki, Greece
| | - M Dalamaga
- Department of Biological Chemistry, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
| | - A Stratigos
- 1st Department of Dermatology and Venereology, National and Kapodistrian University of Athens, University of Athens Medical School, "Andreas Sygros" Hospital for Skin Diseases, Athens, Greece
| |
Collapse
|
4
|
Panou E, Nikolaou V, Marinos L, Kallambou S, Sidiropoulou P, Gerochristou M, Stratigos A. Recurrence of cutaneous T-cell lymphoma post viral vector COVID-19 vaccination. J Eur Acad Dermatol Venereol 2022; 36:e91-e93. [PMID: 34628691 PMCID: PMC9088536 DOI: 10.1111/jdv.17736] [Citation(s) in RCA: 21] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- E. Panou
- 1st Dermatology DepartmentAndreas Syggros Hospital for Skin DiseasesNational & Kapodestrian University of Athens Medical SchooolAthensGreece
| | - V. Nikolaou
- 1st Dermatology DepartmentAndreas Syggros Hospital for Skin DiseasesNational & Kapodestrian University of Athens Medical SchooolAthensGreece
| | - L. Marinos
- Department of HemopathologyEvangelismos HospitalAthensGreece
| | - S. Kallambou
- 1st Dermatology DepartmentAndreas Syggros Hospital for Skin DiseasesNational & Kapodestrian University of Athens Medical SchooolAthensGreece
| | - P. Sidiropoulou
- 1st Dermatology DepartmentAndreas Syggros Hospital for Skin DiseasesNational & Kapodestrian University of Athens Medical SchooolAthensGreece
| | - M. Gerochristou
- 1st Dermatology DepartmentAndreas Syggros Hospital for Skin DiseasesNational & Kapodestrian University of Athens Medical SchooolAthensGreece
| | - A. Stratigos
- 1st Dermatology DepartmentAndreas Syggros Hospital for Skin DiseasesNational & Kapodestrian University of Athens Medical SchooolAthensGreece
| |
Collapse
|
5
|
Apalla Z, Nikolaou V, Fattore D, Fabbrocini G, Freites-Martinez A, Sollena P, Lacouture M, Kraehenbuehl L, Stratigos A, Peris K, Lazaridou E, Richert B, Vigarios E, Riganti J, Baroudjian B, Filoni A, Dodiuk-Gad R, Lebbé C, Sibaud V. European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force 'Dermatology for cancer patients' position statement. J Eur Acad Dermatol Venereol 2021; 36:332-350. [PMID: 34910332 DOI: 10.1111/jdv.17855] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2021] [Revised: 11/10/2021] [Accepted: 11/18/2021] [Indexed: 12/14/2022]
Abstract
The introduction of immune checkpoint inhibitors (ICIs) opened a new era in oncologic therapy. The favourable profile of ICIs in terms of efficacy and safety can be overshadowed by the development of immune-related adverse events (irAEs). Dermatologic irAEs (dirAEs) appear in about 40% of patients undergoing immunotherapy and mainly include maculopapular, psoriasiform, lichenoid and eczematous rashes, auto-immune bullous disorders, pigmentary disorders, pruritus, oral mucosal lesions, hair and nail changes, as well as a few rare and potentially life-threatening toxicities. The EADV task force Dermatology for Cancer Patients merged the clinical experience of the so-far published data, incorporated the quantitative and qualitative characteristics of each specific dirAEs, and released dermatology-derived, phenotype-specific treatment recommendations for cutaneous toxicities (including levels of evidence and grades of recommendation). The basic principle of management is that the interventions should be tailored to serve the equilibrium between patients' relief from the symptoms and signs of skin toxicity and the preservation of an unimpeded oncologic treatment.
Collapse
Affiliation(s)
- Z Apalla
- Second Dermatology Department, Medical School, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - V Nikolaou
- First Department of Dermatology, "Andreas Sygros" Hospital for Skin Diseases, National and Kapodestrian University of Athens, Medical School, Athens, Greece
| | - D Fattore
- Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
| | - G Fabbrocini
- Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
| | - A Freites-Martinez
- Servicio de Dermatología, Hospital Ruber Juan Bravo y Universidad Europea, Madrid, España
| | - P Sollena
- Dipartimento di Scienze Mediche e Chirurgiche, Dermatologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.,Dermatologia, Università Cattolica del Sacro Cuore, Rome, Italy
| | - M Lacouture
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - L Kraehenbuehl
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.,Parker Institute for Cancer Immunotherapy, Ludwig Collaborative and Swim Across America Laboratory, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.,Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
| | - A Stratigos
- First Department of Dermatology, "Andreas Sygros" Hospital for Skin Diseases, National and Kapodestrian University of Athens, Medical School, Athens, Greece
| | - K Peris
- Dipartimento di Scienze Mediche e Chirurgiche, Dermatologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.,Dermatologia, Università Cattolica del Sacro Cuore, Rome, Italy
| | - E Lazaridou
- Second Dermatology Department, Medical School, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - B Richert
- Department of Dermatology, Brugmann & Saint-Pierre University Hospital, Université Libre de Bruxelles, Brussels, Belgium
| | - E Vigarios
- Department of Oral Medicine, Institut Claudius Regaud, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France
| | - J Riganti
- Hospital Italiano of Buenos Aires, Buenos Aires, Argentina
| | - B Baroudjian
- Dermatology Department, Saint Louis Hospital, Université de Paris, AP-HP, INSERM U976, Paris, France
| | - A Filoni
- Section of Dermatology, Department of Biomedical Science and Human Oncology, University of Bari, Bari, Italy
| | - R Dodiuk-Gad
- Dermatology Department, Emek Medical Center, Afula, Israel
| | - C Lebbé
- Dermatology Department, Saint Louis Hospital, Université de Paris, AP-HP, INSERM U976, Paris, France
| | - V Sibaud
- Oncodermatology Department, Cancer University Institute, Toulouse Oncopole, Toulouse, France
| |
Collapse
|
6
|
Patsatsi A, Papadavid E, Kyriakou A, Georgiou E, Koletsa T, Avgeros C, Koumourtzis M, Lampadaki K, Tsamaldoupis A, Lazaridou E, Stratigos A, Nikolaou V. The use of pegylated interferon a-2a in a cohort of Greek patients with mycosis fungoides. J Eur Acad Dermatol Venereol 2021; 36:e291-e293. [PMID: 34753217 DOI: 10.1111/jdv.17795] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- A Patsatsi
- 2nd Department of Dermatology and Venereology, School of Medicine, Aristotle University of Thessaloniki, "Papageorgiou" General Hospital, Thessaloniki, Greece
| | - E Papadavid
- 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, "Attikon" University General Hospital, Athens, Greece
| | - A Kyriakou
- 2nd Department of Dermatology and Venereology, School of Medicine, Aristotle University of Thessaloniki, "Papageorgiou" General Hospital, Thessaloniki, Greece
| | - E Georgiou
- 2nd Department of Dermatology and Venereology, School of Medicine, Aristotle University of Thessaloniki, "Papageorgiou" General Hospital, Thessaloniki, Greece.,Laboratory of Biological Chemistry, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - T Koletsa
- Department of Pathology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - C Avgeros
- Laboratory of Biological Chemistry, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - M Koumourtzis
- 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, "Attikon" University General Hospital, Athens, Greece
| | - K Lampadaki
- 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, "Attikon" University General Hospital, Athens, Greece
| | - A Tsamaldoupis
- 2nd Department of Dermatology and Venereology, School of Medicine, Aristotle University of Thessaloniki, "Papageorgiou" General Hospital, Thessaloniki, Greece
| | - E Lazaridou
- 2nd Department of Dermatology and Venereology, School of Medicine, Aristotle University of Thessaloniki, "Papageorgiou" General Hospital, Thessaloniki, Greece
| | - A Stratigos
- 1st Department of Dermatology and Venereology, National and Kapodistrian University of Athens, University of Athens Medical School, "Andreas Sygros" Hospital for skin diseases, Athens, Greece
| | - V Nikolaou
- 1st Department of Dermatology and Venereology, National and Kapodistrian University of Athens, University of Athens Medical School, "Andreas Sygros" Hospital for skin diseases, Athens, Greece
| |
Collapse
|
7
|
Grob JJ, Guminski A, Malvehy J, Basset-Seguin N, Bertrand B, Fernandez-Penas P, Kaufmann R, Zalaudek I, Gaudy-Marqueste C, Fargnoli MC, Tagliaferri L, Fertil B, Del Marmol V, Stratigos A, Garbe C, Peris K. Position statement on classification of basal cell carcinomas. Part 1: unsupervised clustering of experts as a way to build an operational classification of advanced basal cell carcinoma based on pattern recognition. J Eur Acad Dermatol Venereol 2021; 35:1949-1956. [PMID: 34432327 PMCID: PMC8518046 DOI: 10.1111/jdv.17466] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2021] [Accepted: 05/18/2021] [Indexed: 12/01/2022]
Abstract
Background No simple classification system has emerged for ‘advanced basal cell carcinomas’, and more generally for all difficult‐to‐treat BCCs (DTT‐BCCs), due to the heterogeneity of situations, TNM inappropriateness to BCCs, and different approaches of different specialists. Objective To generate an operational classification, using the unconscious ability of experts to simplify the great heterogeneity of the clinical situations into a few relevant groups, which drive their treatment decisions. Method Non‐supervised independent and blinded clustering of real clinical cases of DTT‐BCCs was used. Fourteen international experts from different specialties independently partitioned 199 patient cases considered ‘difficult to treat’ into as many clusters they want (≤10), choosing their own criteria for partitioning. Convergences and divergences between the individual partitions were analyzed using the similarity matrix, K‐mean approach, and average silhouette method. Results There was a rather consensual clustering of cases, regardless of the specialty and nationality of the experts. Mathematical analysis showed that consensus between experts was best represented by a partition of DTT‐BCCs into five clusters, easily recognized a posteriori as five clear‐cut patterns of clinical situations. The concept of ‘locally advanced’ did not appear consistent between experts. Conclusion Although convergence between experts was not granted, this experiment shows that clinicians dealing with BCCs all tend to work by a similar pattern recognition based on the overall analysis of the situation. This study thus provides the first consensual classification of DTT‐BCCs. This experimental approach using mathematical analysis of independent and blinded clustering of cases by experts can probably be applied to many other situations in dermatology and oncology.
Collapse
Affiliation(s)
- J J Grob
- Dermatology and skin cancer Dpt APHM Timone, Aix-Marseille University, Marseille, France
| | - A Guminski
- Melanoma Institute Australia, Royal North Shore Hospital, University of Sydney, Sydney, NSW, Australia
| | - J Malvehy
- Department of Dermatology, Hospital Clínic de Barcelona (Melanoma Unit), University of Barcelona, IDIBAPS, Barcelona & CIBERER, Barcelona, Spain
| | | | - B Bertrand
- Plastic, Reconstructive and Aesthetic Surgery Department, Aix-Marseille University, APHM Conception, Marseille, France
| | - P Fernandez-Penas
- Centre for Translational Skin Research, The University of Sydney, Westmead, NSW, Australia.,Department of Dermatology, Westmead Hospital, Westmead, NSW, Australia
| | - R Kaufmann
- Department of Dermatology, Venereology and Allergology, University Hospital, Frankfurt, Germany
| | - I Zalaudek
- Dermatology Clinic, University of Trieste, Trieste, Italy
| | - C Gaudy-Marqueste
- Dermatology and skin cancer Dpt APHM Timone, Aix-Marseille University, Marseille, France
| | - M C Fargnoli
- Department of Dermatology, University of L'Aquila, L'Aquila, Italy
| | - L Tagliaferri
- Dipartimento di Scienze Radiologiche, Radioterapiche Ed Ematologiche, UOC di Radioterapia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - B Fertil
- Anapix Medical, Meyreuil, France
| | - V Del Marmol
- Department of Dermatology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
| | - A Stratigos
- Department of Dermatology- Venereology, School of Medicine, Andreas Sygros Hospital, National and Kapodistrian University of Athens, Athens, Greece
| | - C Garbe
- Department of Dermatology, Centre for Dermatooncology, Eberhard-Karls University, Tuebingen, Germany
| | - K Peris
- Institute of Dermatology, Catholic University of the Sacred Heart, Italy.,IRCCS, Fondazione Policlinico Universitario A. Gemelli, Rome, Italy
| |
Collapse
|
8
|
Grob JJ, Gaudy-Marqueste C, Guminski A, Malvehy J, Basset-Seguin N, Bertrand B, Fernandez-Penas P, Kaufmann R, Zalaudek I, Fargnoli MC, Tagliaferri L, Fertil B, Del Marmol V, Stratigos A, Garbe C, Peris K. Position statement on classification of basal cell carcinomas. Part 2: EADO proposal for new operational staging system adapted to basal cell carcinomas. J Eur Acad Dermatol Venereol 2021; 35:2149-2153. [PMID: 34424580 PMCID: PMC8597032 DOI: 10.1111/jdv.17467] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2021] [Accepted: 04/07/2021] [Indexed: 11/30/2022]
Abstract
Background No simple staging system has emerged for basal cell carcinomas (BCCs), since they do not follow the TNM process, and practitioners failed to agree on simple clinical or pathological criteria as a basis for a classification. Operational classification of BCCs is required for decision‐making, trials and guidelines. Unsupervised clustering of real cases of difficult‐to‐treat BCCs (DTT‐BCCs; part 1) has demonstrated that experts could blindly agree on a five groups classification of DTT‐BCCs based on five patterns of clinical situations. Objective Using this five patterns to generate an operational and comprehensive classification of BCCs. Method Testing practitioner's agreement, when using the five patterns classification to ensure that it is robust enough to be used in the practice. Generating the first version of a staging system of BCCs based on pattern recognition. Results Sixty‐two physicians, including 48 practitioners and the 14 experts who participated in the generation of the five different patterns of DTT‐BCCs, agreed on 90% of cases when classifying 199 DTT‐BCCs cases using the five patterns classification (part 1) attesting that this classification is understandable and usable in practice. In order to cover the whole field of BCCs, these five groups of DTT‐BCCs were added a group representing the huge number of easy‐to‐treat BCCs, for which sub‐classification has little interest, and a group of very rare metastatic cases, resulting in a four‐stage and seven‐substage staging system of BCCs. Conclusion A practical classification adapted to the specificities of BCCs is proposed. It is the first tumour classification based on pattern recognition of clinical situations, which proves to be consistent and usable. This EADO staging system version 1 will be improved step by step and tested as a decision tool and a prognostic instrument.
Collapse
Affiliation(s)
- J J Grob
- Aix-Marseille University, APHM, Marseille, France
| | | | - A Guminski
- Melanoma Institute Australia, Royal North Shore Hospital, University of Sydney, Sydney, NSW, Australia
| | - J Malvehy
- Department of Dermatology, Hospital Clínic de Barcelona (Melanoma Unit), University of Barcelona, IDIBAPS, Barcelona & CIBERER, Barcelona, Spain
| | | | - B Bertrand
- Plastic, Reconstructive and Aesthetic Surgery Department, La Conception Hospital, Marseille, France
| | - P Fernandez-Penas
- Centre for Translational Skin Research, The University of Sydney, Westmead, NSW, Australia.,Department of Dermatology, Westmead Hospital, Westmead, NSW, Australia
| | - R Kaufmann
- Department of Dermatology, Venereology and Allergology, University Hospital Frankfurt, Frankfurt, Germany
| | - I Zalaudek
- Dermatology Clinic, University of Trieste, Trieste, Italy
| | - M C Fargnoli
- Department of Dermatology, University of L'Aquila, L'Aquila, Italy
| | - L Tagliaferri
- Dipartimento di Scienze Radiologiche, Radioterapiche Ed Ematologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC di Radioterapia, Rome, Italy
| | - B Fertil
- Anapix Medical, Meyreuil, France
| | - V Del Marmol
- Department of Dermatology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
| | - A Stratigos
- Department of Dermatology- Venereology, National and Kapodistrian University of Athens, School of Medicine, Andreas Sygros Hospital, Athens, Greece
| | - C Garbe
- Centre for Dermatooncology, Department of Dermatology, Eberhard-Karls University, Tuebingen, Germany
| | - K Peris
- Institute of Dermatology, Catholic University of the Sacred Heart, Rome, Italy.,Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy
| |
Collapse
|
9
|
Gregoriou S, Kleidona IA, Tsimpidakis A, Nicolaidou E, Stratigos A, Rigopoulos D. 'COVID vaccine arm' may present after both mRNA vaccines vaccination. J Eur Acad Dermatol Venereol 2021; 35:e867-e868. [PMID: 34416053 PMCID: PMC8657342 DOI: 10.1111/jdv.17614] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2021] [Revised: 07/29/2021] [Accepted: 08/13/2021] [Indexed: 11/30/2022]
Affiliation(s)
- S Gregoriou
- 1st Department of Dermatology-Venereology, Andreas Sygros Hospital, National and Kapodistrian University of Athens, I. Dragoumi 5, Athens, 16121, Greece
| | - I A Kleidona
- 1st Department of Dermatology-Venereology, Andreas Sygros Hospital, National and Kapodistrian University of Athens, I. Dragoumi 5, Athens, 16121, Greece
| | - A Tsimpidakis
- 1st Department of Dermatology-Venereology, Andreas Sygros Hospital, National and Kapodistrian University of Athens, I. Dragoumi 5, Athens, 16121, Greece
| | - E Nicolaidou
- 1st Department of Dermatology-Venereology, Andreas Sygros Hospital, National and Kapodistrian University of Athens, I. Dragoumi 5, Athens, 16121, Greece
| | - A Stratigos
- 1st Department of Dermatology-Venereology, Andreas Sygros Hospital, National and Kapodistrian University of Athens, I. Dragoumi 5, Athens, 16121, Greece
| | - D Rigopoulos
- 1st Department of Dermatology-Venereology, Andreas Sygros Hospital, National and Kapodistrian University of Athens, I. Dragoumi 5, Athens, 16121, Greece
| |
Collapse
|
10
|
Velissari A, Lakiotaki E, Nikolaou V, Argyropoulos KV, Stratigos A, Daikos G, Konstantopoulos K, Siakantaris M. Genetic polymorphisms in immunity related genes and the vitamin D receptor gene and risk of cutaneous T-cell lymphoma in Greek population. J Eur Acad Dermatol Venereol 2021; 35:e805-e807. [PMID: 34173274 DOI: 10.1111/jdv.17482] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2021] [Revised: 05/23/2021] [Accepted: 06/10/2021] [Indexed: 11/29/2022]
Affiliation(s)
- A Velissari
- Hematology Department, Laiko General Hospital, National and Kapodistrian University of Athens, Athens, Greece
| | - E Lakiotaki
- First Department of Pathology, Medical School, National and Kapodistrian University of Athens, Athens, Greece
| | - V Nikolaou
- 1st Department of Dermatology, A. Syggros Hospital for Skin Diseases, Athens, Greece
| | - K V Argyropoulos
- Department of Pathology, School of Medicine, New York University, New York, NY, USA
| | - A Stratigos
- 1st Department of Dermatology, A. Syggros Hospital for Skin Diseases, Athens, Greece
| | - G Daikos
- First Department of Internal Medicine, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece
| | - K Konstantopoulos
- Hematology Department, Laiko General Hospital, National and Kapodistrian University of Athens, Athens, Greece
| | - M Siakantaris
- Hematology Department, Laiko General Hospital, National and Kapodistrian University of Athens, Athens, Greece
| |
Collapse
|
11
|
Siskou S, Lallas A, Theodoropoulos K, Sgouros D, Trakatelli M, Patsatsi A, Trigoni A, Manoli M, Papageorgiou C, Liopyris K, Katoulis A, Stratigos A, Ioannides D, Lazaridou E, Apalla Z. Diagnostic and management challenges of erosive pustular dermatosis of the scalp: a retrospective study in Greek population. J Eur Acad Dermatol Venereol 2021; 35:e776-e779. [PMID: 34143550 DOI: 10.1111/jdv.17455] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- S Siskou
- Second Dermatology Department, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.,Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK
| | - A Lallas
- Dermomedica, Dermatology Unit, Thessaloniki, Greece.,First Dermatology Department, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - K Theodoropoulos
- Second Dermatology Department, Kapodistrian University of Athens, Attikon Hospital, Athens, Greece
| | - D Sgouros
- Second Dermatology Department, Kapodistrian University of Athens, Attikon Hospital, Athens, Greece
| | - M Trakatelli
- Second Dermatology Department, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - A Patsatsi
- Second Dermatology Department, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - A Trigoni
- Second Dermatology Department, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - M Manoli
- Dermomedica, Dermatology Unit, Thessaloniki, Greece.,First Dermatology Department, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - C Papageorgiou
- Second Dermatology Department, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.,Dermomedica, Dermatology Unit, Thessaloniki, Greece
| | - K Liopyris
- First Dermatology Department, Kapodistrian University of Athens, A. Syggros Hospital, Athens, Greece
| | - A Katoulis
- Second Dermatology Department, Kapodistrian University of Athens, Attikon Hospital, Athens, Greece
| | - A Stratigos
- First Dermatology Department, Kapodistrian University of Athens, A. Syggros Hospital, Athens, Greece
| | - D Ioannides
- First Dermatology Department, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - E Lazaridou
- Second Dermatology Department, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - Z Apalla
- Second Dermatology Department, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.,Dermomedica, Dermatology Unit, Thessaloniki, Greece
| |
Collapse
|
12
|
Klavdianou K, Stavropoulou M, Panagakis P, Papoutsaki M, Panagiotopoulos A, Koutsianas C, Stratigos A, Rigopoulos D, Vassilopoulos D. AB0543 CHARACTERISTICS AND TREATMENT CHANGES IN PATIENTS WITH PSORIATIC ARTHRITIS SEEN IN A COMBINED DERMATOLOGY-RHEUMATOLOGY CLINIC. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.1640] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Data on patients with Psoriasis (PSO) referred to a combined Dermatology-Rheumatology outpatient Clinic (Derm-Rheum) with suspected psoriatic arthritis (PsA) are limited.Objectives:To assess patient characteristics and treatment changes in PsA patients referred to a Derm-Rheum Clinic.Methods:Prospective study of PSO patients referred to a combined Derm - Rheum Clinic from February 2018 to June 2020 in a Tertiary University Hospital.Results:Among 151 patients with PSO referred to the Clinic, 129 (85%) with a final diagnosis of PsA were included. In 73% of patients (n=94) PsA was diagnosed there for the 1st time. 56% were females with a mean age of 55 years and a median disease duration of 14.2 years. At initial evaluation, 95% had peripheral arthritis, 45% nail involvement, 23% axial involvement, 12% enthesitis and 6% dactylitis with a median DAPSA score of 20.5 and PASI score of 1.6, respectively. 31% of the patients were not receiving any systemic treatment, 45% were on biologics (30% as monotherapy, 15% in combination with non-biologics), 29% were on non-biologics (14% as monotherapy, 15% in combination with biologics or targeted synthetic agents] and 10% were on targeted synthetic (ts) agents. At last visit (median follow-up: 15 months) only 8% did not receive any systemic therapy (p<0.001 compared to 1st visit), 62% were on biologics (39% monotherapy – 23% in combination with non-biologics, p=0.009), 46% were on non-biologics (20% as monotherapy – 26% in combination with biologics or ts agents, p=0.01) and 10% of the patients were on apremilast. The median DAPSA and PASI scores at last visit were 5.3 and 0, respectively.Conclusion:About 2/3 of patients with PSO referred to a combined Derm - Rheum Clinic with suspicious musculoskeletal complaints were diagnosed for the 1st time as PsA. During follow-up the percentage of PsA patients who started or continued systemic therapy significantly increased with significant improvement of disease activity indices. These data emphasize the value of combined Derm - Rheum Clinics for earlier diagnosis and more efficacious treatment of PsA patients.Acknowledgements:This work was supported by research grants from the Special Account for Research Grants (S.A.R.G.), National and Kapodistrian University of Athens, Athens, Greece.Disclosure of Interests:None declared.
Collapse
|
13
|
Niforou A, Sgouros D, Lallas A, Zaras A, Scope A, Tsao H, Argenziano G, Longo C, Kittler H, Stratigos A. The spectrum of morphologic patterns of nodular melanoma: a study of the International Dermoscopy Society. J Eur Acad Dermatol Venereol 2021; 35:e762-e765. [PMID: 34058031 DOI: 10.1111/jdv.17428] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2021] [Accepted: 05/19/2021] [Indexed: 01/13/2023]
Affiliation(s)
- A Niforou
- 1st Department of Dermatology-Venereology, Andreas Sygros Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece
| | - D Sgouros
- 1st Department of Dermatology-Venereology, Andreas Sygros Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece
| | - A Lallas
- 1st Department of Dermatology, Aristotle University, Thessaloniki, Greece
| | - A Zaras
- 1st Department of Dermatology-Venereology, Andreas Sygros Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece
| | - A Scope
- The Kittner Skin Cancer Screening & Research Institute, Sheba Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - H Tsao
- Wellman Center for Photomedicine at Massachusetts General Hospital, Boston, MA, USA.,Massachusetts General Hospital Cancer Center, Boston, MA, USA
| | - G Argenziano
- Dermatology Unit, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - C Longo
- Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italy.,Centro Oncologico ad Alta Tecnologia Diagnostica, Azienda Unit a Sanitaria Locale - IRCCS di Reggio Emilia, Reggio Emilia, Italy
| | - H Kittler
- Department of Dermatology, Medical University of Vienna, Vienna, Austria
| | - A Stratigos
- 1st Department of Dermatology-Venereology, Andreas Sygros Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece
| | | |
Collapse
|
14
|
Tyros G, Papageorgiou C, Kanelleas A, Kotsafti O, Spyridonos E, Gregoriou S, Tagka A, Stratigos A, Nicolaidou E. The effect of anxiety, psychopathological symptoms and personality traits on response to treatment in male patients with anogenital warts: a prospective study. J Eur Acad Dermatol Venereol 2021; 35:1859-1864. [PMID: 33914981 DOI: 10.1111/jdv.17324] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2021] [Accepted: 04/13/2021] [Indexed: 12/01/2022]
Abstract
BACKGROUND In the era of precision medicine, identification of possible predictive factors of clinical response to treatment is fundamental. This need is particularly strong for anogenital warts (AGW), because there are several treatment modalities with different clearance and recurrence rates. However, data regarding the effect of mental health parameters on response to treatment in patients with AGW are lacking. OBJECTIVES The purpose of the present study was to evaluate the association between patients' mental health parameters and AGW treatment outcomes. METHODS This was a single-centre, prospective study that included newly diagnosed male patients with AGW. At their initial visit, all patients completed the State-Trait Anxiety Inventory (STAI), the Symptom Checklist-90-Revised (SCL-90-R) and the Eysenck Personality Questionnaire (EPQ) questionnaires, which evaluate anxiety, psychopathological manifestations and personality traits, respectively. All patients received cryotherapy until clearance of lesions and were followed up for 18 months for detection of recurrences. RESULTS The study included 167 male patients. The mean number of days for AGW clearance was 89 ± 65. During the 18-month follow-up, 28% of participants showed a recurrence, after a mean number of 150 ± 132 days. No statistically significant association was detected between questionnaires scores and (a) time needed for AGW clearance, (b) time until 1st recurrence and (c) number of recurrences. CONCLUSION If confirmed, our findings indicate that we may not need to modify our AGW treatment plan according to a patient's mental health profile.
Collapse
Affiliation(s)
- G Tyros
- 1st Department of Dermatology and Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital for Skin and Venereal Diseases, Athens, Greece
| | - C Papageorgiou
- 1st Department of Psychiatry, Medical School, National and Kapodistrian University of Athens, Eginitio Hospital, Athens, Greece
| | - A Kanelleas
- 1st Department of Dermatology and Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital for Skin and Venereal Diseases, Athens, Greece
| | - O Kotsafti
- 1st Department of Dermatology and Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital for Skin and Venereal Diseases, Athens, Greece
| | - E Spyridonos
- 1st Department of Dermatology and Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital for Skin and Venereal Diseases, Athens, Greece
| | - S Gregoriou
- 1st Department of Dermatology and Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital for Skin and Venereal Diseases, Athens, Greece
| | - A Tagka
- 1st Department of Dermatology and Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital for Skin and Venereal Diseases, Athens, Greece
| | - A Stratigos
- 1st Department of Dermatology and Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital for Skin and Venereal Diseases, Athens, Greece
| | - E Nicolaidou
- 1st Department of Dermatology and Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital for Skin and Venereal Diseases, Athens, Greece
| |
Collapse
|
15
|
Kandolf-Sekulovic L, Peris K, Stratigos A, Hauschild A, Forsea AM, Lebbe C, Lallas A, Grob JJ, Harwood C, Gogas H, Rutkowski P, Olah J, Kelleners-Smeets NWJ, Paoli J, Dummer R, Moreno-Ramirez D, Bastholt L, Putnik K, Karls R, Hoeller C, Vandersleyen V, Vieira R, Arenberger P, Bylaite-Buckinskiene M, Ocvirk J, Situm M, Weinlich G, Banjin M, Todorovic V, Ymeri A, Zhukavets A, Garbe C. Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centres in 27 European countries. J Eur Acad Dermatol Venereol 2020; 35:1119-1132. [PMID: 33326646 DOI: 10.1111/jdv.17086] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2020] [Accepted: 11/20/2020] [Indexed: 12/26/2022]
Abstract
BACKGROUND AND OBJECTIVES The incidence of melanoma is increasing. This places significant burden on societies to provide efficient cancer care. The European Cancer Organisation recently published the essential requirements for quality melanoma care. The present study is aimed for the first time to roughly estimate the extent to which these requirements have been met in Europe. MATERIALS AND METHODS A web-based survey of experts from melanoma centres in 27 European countries was conducted from 1 February to 1 August 2019. Data on diagnostic techniques, surgical and medical treatment, organization of cancer care and education were collected and correlated with national health and economic indicators and mortality-to-incidence ratio (MIR) as a surrogate for survival. Univariate linear regression analysis was performed to evaluate the correlations. SPSS software was used. Statistical significance was set at P < 0.05. RESULTS The MIR was lower in countries with a high health expenditure per capita and with a higher numbers of general practitioners (GPs) and surgeons (SURG) per million inhabitants. In these countries, GPs and dermatologists (DER) were involved in melanoma detection; high percentage of DER used dermatoscopy and were involved in the follow-up of all melanoma stages; both medical oncologists (ONC) and dermato-oncologists administered systemic treatments; and patients had better access to sentinel lymph node biopsy and were treated within multidisciplinary tumour boards. CONCLUSION Based on these first estimates, the greater involvement of GPs in melanoma detection; the greater involvement of highly trained DER in dermatoscopy, dermatosurgery, follow-up and the systemic treatment of melanoma; and the provision of ongoing dermato-oncology training for pathologists, SURG, DER and ONC are necessary to provide an optimal melanoma care pathway. A comprehensive analysis of the melanoma care pathway based on clinical melanoma registries will be needed to more accurately evaluate these first insights.
Collapse
Affiliation(s)
- L Kandolf-Sekulovic
- Department of Dermatology, Faculty of Medicine, Military Medical Academy, Belgrade, Serbia
| | - K Peris
- Institute of Dermatology, Catholic University of the Sacred Heart, Rome, Italy
| | - A Stratigos
- 1st Department of Dermatology-Venereology, Andreas Sygros Hospital, National and Kapodistrian University of Athens, Athens, Greece
| | - A Hauschild
- Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Kiel, Germany
| | - A-M Forsea
- Elias University Hospital Bucharest, Carol Davila University of Medicine and Pharmacy, Bucuresti, Romania
| | - C Lebbe
- APHP Dermatology Department, University Paris 7 Diderot, INSERM U976, Paris, France
| | - A Lallas
- First Department of Dermatology, Aristotle University, Thessaloniki, Greece
| | - J-J Grob
- Service de Dermatologie et Cancérologie Cutanée, Hopital de la Timone, Marseille, France
| | - C Harwood
- Centre for Cell Biology and Cutaneous Research, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
| | - H Gogas
- 1st Department of Internal Medicine, Laiko Hospital, National and Kapodistrian University of Athens, Athens, Greece
| | - P Rutkowski
- Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland
| | - J Olah
- Department of Oncotherapy, Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary
| | - N W J Kelleners-Smeets
- Department of Dermatology, Maastricht University Medical Center, Maastricht, the Netherlands
| | - J Paoli
- Department of Dermatology and Venereology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - R Dummer
- UniversitätsSpital Zürich-Skin Cancer Center, University Hospital, Zürich, Switzerland
| | - D Moreno-Ramirez
- Department of Clinical Oncology, Hospital Universitario Virgen Macarena, Sevilla, Spain
| | - L Bastholt
- Department of Oncology, Odense University Hospital, Odense, Denmark
| | - K Putnik
- North Estonia Medical Centre, Tallinn, Estonia
| | - R Karls
- Derma Clinic Riga, Riga, Latvia
| | - C Hoeller
- Department of Dermatology, Medical University of Vienna, Vienna, Austria
| | - V Vandersleyen
- Department of Medical Oncology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel (VUB), Brussels, Belgium
| | - R Vieira
- Department of Dermatology, Medical Faculty, University of Coimbra, Coimbra, Portugal
| | - P Arenberger
- Department of Dermatovenereology, Charles University 3rd Faculty of Medicine and University Hospital Kralovske Vinohrady, Prague, Czech Republic
| | | | - J Ocvirk
- Institute of Oncology Ljubljana, Ljubljana, Slovenia
| | - M Situm
- Department of Oncology, University Hospital Zagreb, Zagreb, Croatia
| | - G Weinlich
- Department of Dermatology, Venerology and Allergology, Medical University of Innsbruck, Innsbruck, Austria
| | - M Banjin
- Department of Oncology, University Hospital Sarajevo, Sarajevo, Bosnia and Herzegovina
| | - V Todorovic
- Clinic for Oncology and radiotherapy, Podgorica, Montenegro
| | - A Ymeri
- University Hospital Mother Theresa, Tirana, Albania
| | - A Zhukavets
- Belarusian Medical Academy of Postgraduate Education (BelMAPE), Minsk, Belarus
| | - C Garbe
- Centre for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany
| |
Collapse
|
16
|
John SM, Garbe C, French LE, Takala J, Yared W, Cardone A, Gehring R, Spahn A, Stratigos A. Improved protection of outdoor workers from solar ultraviolet radiation: position statement. J Eur Acad Dermatol Venereol 2020; 35:1278-1284. [PMID: 33222341 DOI: 10.1111/jdv.17011] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2020] [Accepted: 10/15/2020] [Indexed: 12/26/2022]
Abstract
The vast majority of non-melanoma skin cancer (NMSC) is attributable to excessive exposure to ultraviolet radiation (UVR). Outdoor workers are exposed to an UVR dose at least 2 to 3 times higher than indoor workers and often to daily UVR doses 5 times above internationally recommended limits. The risk of UVR workplace exposure is vastly neglected, and the evident future challenges presented in this statement are contrasted with the current situation regarding legal recognition, patient care and compensation. While prevention is crucial to reduce cancer risks for outdoor workers, it is as much of relevance to better protect them through legally binding rules and regulations. Specific actions are outlined in five recommendations based on a Call to Action (table 1). The role of health professionals, including dermatologists, in this context is crucial.
Collapse
Affiliation(s)
- S M John
- EADV Task Force Occupational Skin Diseases and Dept. Dermatology, Environmental Medicine, University of Osnabrueck, Osnabrueck, Germany
| | - C Garbe
- European Association of Dermato Oncology (EADO) and Department of Dermatology, Eber, hard Karls University, Tübingen, Germany
| | - L E French
- International League of Dermatological Societies (ILDS) and Department of Dermatology, University Hospital, Ludwig-Maximilians-University of Munich, Munich, Germany
| | - J Takala
- International Commission on Occupational Health (ICOH), University of Tampere, Tampere, Finland
| | - W Yared
- European Cancer Leagues (ECL), Brussels, Belgium
| | - A Cardone
- European Cancer Patient Coalition (ECPC), Brussels, Belgium
| | - R Gehring
- Safety and Health, European Federation Building and Woodworkers (EFBWW), Brussels, Belgium
| | - A Spahn
- Agriculture Section, European Federation of Food, Agriculture and Tourism Trade Unions (EFFAT), Brussels, Belgium
| | - A Stratigos
- European Academy of Dermatology and Venereology (EADV) and Dept. Dermatology, National and Kapodistrian University of Athens, Athens, Greece
| |
Collapse
|
17
|
Talaganis J, Gregoriou S, Stratigos A. Stress and melanoma. Myth or reality? Br J Dermatol 2020; 183:607-608. [DOI: 10.1111/bjd.19035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- J.A. Talaganis
- First Department of Dermatology‐Venereology National and Kapodistrian University of Athens Faculty of Medicine, ‘A. Sygros’ Hospital for Cutaneous & Venereal Diseases Athens Greece
| | - S. Gregoriou
- First Department of Dermatology‐Venereology National and Kapodistrian University of Athens Faculty of Medicine, ‘A. Sygros’ Hospital for Cutaneous & Venereal Diseases Athens Greece
| | - A.J. Stratigos
- First Department of Dermatology‐Venereology National and Kapodistrian University of Athens Faculty of Medicine, ‘A. Sygros’ Hospital for Cutaneous & Venereal Diseases Athens Greece
| |
Collapse
|
18
|
Stratigos A, Sekulic A, Peris K, Bechter O, Dutriaux C, Kaatz M, Lewis K, Basset-Seguin N, Chang A, Dalle S, Fernandez-Orland A, Licitra L, Robert C, Ulrich C, Hauschild A, Migden M, Dummer R, Li S, Bowler T, Fury M. LBA47 Primary analysis of phase II results for cemiplimab in patients (pts) with locally advanced basal cell carcinoma (laBCC) who progress on or are intolerant to hedgehog inhibitors (HHIs). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.2277] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
19
|
Sgouros D, Lallas A, Kittler H, Zarras A, Kyrgidis A, Papageorgiou C, Puig S, Scope A, Argenziano G, Zalaudek I, Pizzichetta MA, Marghoob A, Liopyris K, Malvehy J, Oikonomou C, Flórez A, Braun R, Cabo H, Nazzaro G, Lanssens S, Menzies S, Paoli J, Kaminska-Winciorek G, Longo C, Katoulis A, Apalla Z, Ioannides D, Thomas L, Tromme I, Ogata D, Desinioti C, Geller A, Stratigos A. Dermatoscopic features of thin (≤2 mm Breslow thickness) vs. thick (>2 mm Breslow thickness) nodular melanoma and predictors of nodular melanoma versus nodular non-melanoma tumours: a multicentric collaborative study by the International Dermoscopy Society. J Eur Acad Dermatol Venereol 2020; 34:2541-2547. [PMID: 32654237 DOI: 10.1111/jdv.16815] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2020] [Accepted: 07/02/2020] [Indexed: 12/16/2022]
Abstract
BACKGROUND Thin nodular melanoma (NM) often lacks conspicuous melanoma-specific dermatoscopic criteria and escapes clinical detection until it progresses to a thicker and more advanced tumour. OBJECTIVE To investigate the dermatoscopic morphology of thin (≤2 mm Breslow thickness) vs. thick (>2 mm) NM and to identify dermatoscopic predictors of its differential diagnosis from other nodular tumours. METHODS Retrospective, morphological case-control study, conducted on behalf of the International Dermoscopy Society. Dermatoscopic images of NM and other nodular tumours from 19 skin cancer centres worldwide were collected and analysed. RESULTS Overall, 254 tumours were collected (69 NM of Breslow thickness ≤2 mm, 96 NM >2 mm and 89 non-melanoma nodular lesions). Light brown coloration (50.7%) and irregular brown dots/globules (42.0%) were most frequently observed in ≤2 mm NMs. Multivariate analysis revealed that dotted vessels (3.4-fold), white shiny streaks (2.9-fold) and irregular blue structureless area (2.4-fold) were predictors for thinner NM compared to non-melanoma nodular tumours. Overall, irregular blue structureless area (3.4-fold), dotted vessels (4.6-fold) and serpentine vessels (1.9-fold) were predictors of all NM compared to non-melanoma nodular lesions. LIMITATIONS Absence of a centralized, consensus pathology review and cases selected form tertiary centres maybe not reflecting the broader community. CONCLUSIONS Our study sheds light into the dermatoscopic morphology of thin NM in comparison to thicker NM and could provide useful clues for its differential diagnosis from other non-melanoma nodular tumours.
Collapse
Affiliation(s)
- D Sgouros
- 1st Department of Dermatology-Venereology, Andreas Sygros Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece
| | - A Lallas
- 1st Department of Dermatology, Aristotle University, Thessaloniki, Greece
| | - H Kittler
- Department of Dermatology, Medical University of Vienna, Vienna, Austria
| | - A Zarras
- 1st Department of Dermatology-Venereology, Andreas Sygros Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece
| | - A Kyrgidis
- Department of Clinical Pharmacology, Aristotle University, Thessaloniki, Greece
| | - C Papageorgiou
- 1st Department of Dermatology, Aristotle University, Thessaloniki, Greece
| | - S Puig
- Melanoma Unit, Dermatology Department, Hospital Clinic Barcelona, Universitat de Barcelona IDIBAPS, Barcelona, Spain.,CIBER de Enfermedades Raras, Instituto de Salut de Carlos III, Barcelona, Spain
| | - A Scope
- Medical Screening Institute, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - G Argenziano
- Dermatology Unit, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - I Zalaudek
- Department of Dermatology, University of Trieste, Trieste, Italy
| | - M A Pizzichetta
- Department of Dermatology, University of Trieste, Trieste, Italy.,Division of Medical Oncology - Preventive Oncology, National Cancer Institute, Aviano, Italy
| | - A Marghoob
- Memorial Sloan Kettering Cancer Center, Hauppauge, NY, USA
| | - K Liopyris
- 1st Department of Dermatology-Venereology, Andreas Sygros Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.,Memorial Sloan Kettering Cancer Center, Hauppauge, NY, USA
| | - J Malvehy
- Melanoma Unit, Dermatology Department, Hospital Clinic Barcelona, Universitat de Barcelona IDIBAPS, Barcelona, Spain.,CIBER de Enfermedades Raras, Instituto de Salut de Carlos III, Barcelona, Spain
| | - C Oikonomou
- 1st Department of Dermatology-Venereology, Andreas Sygros Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece
| | - A Flórez
- Department of Dermatology, Pontevedra University Hospital, Pontevedra, Spain
| | - R Braun
- Department of Dermatology, University Hospital Zürich, Zürich, Switzerland
| | - H Cabo
- Dermatology Institute of Medical Reserch, University of Buenos Aires, Buenos Aires, Argentina
| | - G Nazzaro
- Dermatology Unit, Fondazione I.R.C.C.S. Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
| | - S Lanssens
- Private practice Dermatology Maldegem, Maldegem, Belgium
| | - S Menzies
- Discipline of Dermatology, Sydney Medical School, The University of Sydney and Sydney Melanoma Diagnostic Centre, Royal Prince Alfred Hospital, Camperdown, NSW, Australia
| | - J Paoli
- Department of Dermatology and Venereology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.,Region Västra Götaland, Department of Dermatology and Venereology, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - G Kaminska-Winciorek
- Department of Bone Marrow Transplantation and Onco-Hematology, Maria Skłodowska-Curie National Research Institute of Oncology (MSCNRIO), Gliwice Branch, Gliwice, Poland
| | - C Longo
- Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italy.,Centro Oncologico ad Alta Tecnologia Diagnostica, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Reggio Emilia, Italy
| | - A Katoulis
- 2nd Department of Dermatology-Venereology, "Attikon" General University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece
| | - Z Apalla
- State Clinic of Dermatology, Hospital for Skin and Venereal Diseases, Thessaloniki, Greece
| | - D Ioannides
- 1st Department of Dermatology, Aristotle University, Thessaloniki, Greece
| | - L Thomas
- Department of Dermatology, Lyon University, Lyon, France
| | - I Tromme
- Department of Dermatology, King Albert II Institute, Cliniques Universitaires Saint Luc, Brussels, Belgium
| | - D Ogata
- Department of Dermatology, Saitama Medical University, Saitama, Japan
| | - C Desinioti
- 1st Department of Dermatology-Venereology, Andreas Sygros Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece
| | - A Geller
- Department of Social and Behavioral Sciences, Harvard TH School of Public Health, Boston, MA, USA
| | - A Stratigos
- 1st Department of Dermatology-Venereology, Andreas Sygros Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece
| |
Collapse
|
20
|
Misitzis A, Weinstock M, Stratigos A. Comparing interest in indoor tanning among countries with different tanning bed regulations. J Eur Acad Dermatol Venereol 2020; 34:e218-e219. [DOI: 10.1111/jdv.16173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- A. Misitzis
- Department of Dermatology Brown University Providence RI USA
- Center for Dermatoepidemiology Providence VA Medical Center Providence RI USA
- 1st Department of Dermatology National and Kapodistrian University of Athens Athens Greece
| | - M.A. Weinstock
- Department of Dermatology Brown University Providence RI USA
- Center for Dermatoepidemiology Providence VA Medical Center Providence RI USA
| | - A.J. Stratigos
- 1st Department of Dermatology National and Kapodistrian University of Athens Athens Greece
| |
Collapse
|
21
|
Stefanaki C, Soura E, Sgouros D, Leotsakos G, Rigopoulos D, Stratigos A, Kontochrostopoulos G. Nail matrix naevi in children: a prospective study. J Eur Acad Dermatol Venereol 2020; 34:e203-e205. [PMID: 31850539 DOI: 10.1111/jdv.16154] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- C Stefanaki
- Pediatric Dermatology Clinic, Andreas Sygros University Skin Hospital, Athens, Greece
| | - E Soura
- Pediatric Dermatology Clinic, Andreas Sygros University Skin Hospital, Athens, Greece
| | - D Sgouros
- First Dermatology Clinic, Sygros University Skin Hospital, Athens, Greece
| | - G Leotsakos
- Pediatric Dermatology Clinic, Andreas Sygros University Skin Hospital, Athens, Greece
| | - D Rigopoulos
- First Dermatology Clinic, Sygros University Skin Hospital, Athens, Greece
| | - A Stratigos
- First Dermatology Clinic, Sygros University Skin Hospital, Athens, Greece
| | - G Kontochrostopoulos
- Pediatric Dermatology Clinic, Andreas Sygros University Skin Hospital, Athens, Greece
| |
Collapse
|
22
|
Rompoti N, Sidiropoulou P, Panagakis P, Stratigos A, Papoutsaki M, Stefanaki E, Vavouli C, Politou M, Befon A, Kostakis P, Rigopoulos D, Nicolaidou E. Real‐world data from a single Greek centre on the use of secukinumab in plaque psoriasis: effectiveness, safety, drug survival, and identification of patients that sustain optimal response. J Eur Acad Dermatol Venereol 2020; 34:1240-1247. [DOI: 10.1111/jdv.16202] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2019] [Accepted: 12/17/2019] [Indexed: 02/07/2023]
Affiliation(s)
- N. Rompoti
- 1st Department of Dermatology‐Venereology Faculty of Medicine National and Kapodistrian University of Athens “A. Sygros” Hospital for Skin and Venereal Diseases Athens Greece
| | - P. Sidiropoulou
- 1st Department of Dermatology‐Venereology Faculty of Medicine National and Kapodistrian University of Athens “A. Sygros” Hospital for Skin and Venereal Diseases Athens Greece
| | - P. Panagakis
- State Department of Dermatology‐Venereology “A. Sygros” Hospital for Skin and Venereal Diseases Athens Greece
| | - A. Stratigos
- 1st Department of Dermatology‐Venereology Faculty of Medicine National and Kapodistrian University of Athens “A. Sygros” Hospital for Skin and Venereal Diseases Athens Greece
| | - M. Papoutsaki
- 1st Department of Dermatology‐Venereology Faculty of Medicine National and Kapodistrian University of Athens “A. Sygros” Hospital for Skin and Venereal Diseases Athens Greece
| | - E. Stefanaki
- 1st Department of Dermatology‐Venereology Faculty of Medicine National and Kapodistrian University of Athens “A. Sygros” Hospital for Skin and Venereal Diseases Athens Greece
| | - C. Vavouli
- 1st Department of Dermatology‐Venereology Faculty of Medicine National and Kapodistrian University of Athens “A. Sygros” Hospital for Skin and Venereal Diseases Athens Greece
| | - M. Politou
- 1st Department of Dermatology‐Venereology Faculty of Medicine National and Kapodistrian University of Athens “A. Sygros” Hospital for Skin and Venereal Diseases Athens Greece
| | - A. Befon
- State Department of Dermatology‐Venereology “A. Sygros” Hospital for Skin and Venereal Diseases Athens Greece
| | - P. Kostakis
- State Department of Dermatology‐Venereology “A. Sygros” Hospital for Skin and Venereal Diseases Athens Greece
| | - D. Rigopoulos
- 1st Department of Dermatology‐Venereology Faculty of Medicine National and Kapodistrian University of Athens “A. Sygros” Hospital for Skin and Venereal Diseases Athens Greece
| | - E. Nicolaidou
- 1st Department of Dermatology‐Venereology Faculty of Medicine National and Kapodistrian University of Athens “A. Sygros” Hospital for Skin and Venereal Diseases Athens Greece
| |
Collapse
|
23
|
Kostaki M, Plaka M, Stergiopoulou A, Kypreou K, Chardalia V, Befon A, Kostopoulos E, Theologi V, Christofidou E, Chasapi V, Polydorou D, Rigopoulos D, Stratigos A. Subungual melanoma: the experience of a Greek melanoma reference centre from 2003 to 2018. J Eur Acad Dermatol Venereol 2020; 34:e231-e234. [PMID: 31944385 DOI: 10.1111/jdv.16193] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- M Kostaki
- First Department of Dermatology-Venereology of Athens University, Andreas Syggros Hospital, Athens, Greece
| | - M Plaka
- First Department of Dermatology-Venereology of Athens University, Andreas Syggros Hospital, Athens, Greece
| | - A Stergiopoulou
- First Department of Dermatology-Venereology of Athens University, Andreas Syggros Hospital, Athens, Greece
| | - K Kypreou
- First Department of Dermatology-Venereology of Athens University, Andreas Syggros Hospital, Athens, Greece
| | - V Chardalia
- First Department of Dermatology-Venereology of Athens University, Andreas Syggros Hospital, Athens, Greece
| | - A Befon
- First Department of Dermatology-Venereology of Athens University, Andreas Syggros Hospital, Athens, Greece
| | - E Kostopoulos
- First Department of Dermatology-Venereology of Athens University, Andreas Syggros Hospital, Athens, Greece
| | - V Theologi
- First Department of Dermatology-Venereology of Athens University, Andreas Syggros Hospital, Athens, Greece
| | - E Christofidou
- First Department of Dermatology-Venereology of Athens University, Andreas Syggros Hospital, Athens, Greece
| | - V Chasapi
- First Department of Dermatology-Venereology of Athens University, Andreas Syggros Hospital, Athens, Greece
| | - D Polydorou
- First Department of Dermatology-Venereology of Athens University, Andreas Syggros Hospital, Athens, Greece
| | - D Rigopoulos
- First Department of Dermatology-Venereology of Athens University, Andreas Syggros Hospital, Athens, Greece
| | - A Stratigos
- First Department of Dermatology-Venereology of Athens University, Andreas Syggros Hospital, Athens, Greece
| |
Collapse
|
24
|
Longo C, Pampena R, Lallas A, Kyrgidis A, Stratigos A, Peris K, Garbe C, Pellacani G. Adjuvant therapy for cutaneous melanoma: a systematic review and network meta‐analysis of new therapies. J Eur Acad Dermatol Venereol 2020; 34:956-966. [DOI: 10.1111/jdv.16074] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2019] [Accepted: 10/30/2019] [Indexed: 12/19/2022]
Affiliation(s)
- C. Longo
- Department of Dermatology University of Modena and Reggio Emilia Modena Italy
- Centro Oncologico ad Alta Tecnologia Diagnostica Azienda Unità Sanitaria Locale – IRCCS di Reggio Emilia Reggio Emilia Italy
| | - R. Pampena
- Centro Oncologico ad Alta Tecnologia Diagnostica Azienda Unità Sanitaria Locale – IRCCS di Reggio Emilia Reggio Emilia Italy
| | - A. Lallas
- First Department of Dermatology Aristotle University Thessaloniki Greece
| | - A. Kyrgidis
- First Department of Dermatology Aristotle University Thessaloniki Greece
| | - A. Stratigos
- First Department of Dermatology and Venereology National and Kapodistrian University of Athens, A. Sygros Hospital Athens Greece
| | - K. Peris
- Institute of Dermatology Catholic University Rome Italy
- Fondazione Policlinico Universitario A. Gemelli IRCCS Rome Italy
| | - C. Garbe
- Center of Dermato‐oncology University Department of Dermatology Eberhard Karls University Tuebingen Germany
| | - G. Pellacani
- Department of Dermatology University of Modena and Reggio Emilia Modena Italy
| |
Collapse
|
25
|
Kostaki M, Plaka M, Stergiopoulou A, Kypreou K, Chardalia V, Chasapi V, Polydorou D, Stratigos A. Trends in epidemiology of melanoma in situ in Greece: data from a melanoma reference centre during the period 2000-2018. Br J Dermatol 2019; 182:811-813. [PMID: 31549388 DOI: 10.1111/bjd.18551] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- M Kostaki
- First Department of Dermatology-Venereology of Athens University, Andreas Syggros Hospital, Athens, Greece
| | - M Plaka
- First Department of Dermatology-Venereology of Athens University, Andreas Syggros Hospital, Athens, Greece
| | - A Stergiopoulou
- First Department of Dermatology-Venereology of Athens University, Andreas Syggros Hospital, Athens, Greece
| | - K Kypreou
- First Department of Dermatology-Venereology of Athens University, Andreas Syggros Hospital, Athens, Greece
| | - V Chardalia
- First Department of Dermatology-Venereology of Athens University, Andreas Syggros Hospital, Athens, Greece
| | - V Chasapi
- First Department of Dermatology-Venereology of Athens University, Andreas Syggros Hospital, Athens, Greece
| | - D Polydorou
- First Department of Dermatology-Venereology of Athens University, Andreas Syggros Hospital, Athens, Greece
| | - A Stratigos
- First Department of Dermatology-Venereology of Athens University, Andreas Syggros Hospital, Athens, Greece
| |
Collapse
|
26
|
Bokotas C, Gregoriou S, Polydorou D, Plaka M, Kontochristopoulos G, Chasapi V, Stratigos A, Rigopoulos D. Herpetic whitlow mimicking squamous cell carcinoma in an immunocompromised patient. J Eur Acad Dermatol Venereol 2019; 34:e51-e53. [DOI: 10.1111/jdv.15898] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- C. Bokotas
- Department of Dermatology “A. Sygros” Hospital Athens Greece
| | - S. Gregoriou
- 1st Department of Dermatology and Venereology, National and Kapodistrian University of Athens “A. Sygros” Hospital Athens Greece
| | - D. Polydorou
- Department of Dermatology “A. Sygros” Hospital Athens Greece
| | - M. Plaka
- Department of Dermatology “A. Sygros” Hospital Athens Greece
| | | | - V. Chasapi
- Department of Dermatology “A. Sygros” Hospital Athens Greece
| | - A. Stratigos
- 1st Department of Dermatology and Venereology, National and Kapodistrian University of Athens “A. Sygros” Hospital Athens Greece
| | - D. Rigopoulos
- 1st Department of Dermatology and Venereology, National and Kapodistrian University of Athens “A. Sygros” Hospital Athens Greece
| |
Collapse
|
27
|
Affiliation(s)
- E. Soura
- Center for Melanoma and Skin Cancer 1st University Department of Dermatology‐ Venereology Andreas Sygros Hospital National and Kapodistrian University School of Medicine Athens Greece
| | - A. Stratigos
- Center for Melanoma and Skin Cancer 1st University Department of Dermatology‐ Venereology Andreas Sygros Hospital National and Kapodistrian University School of Medicine Athens Greece
| |
Collapse
|
28
|
Scarisbrick JJ, Quaglino P, Prince HM, Papadavid E, Hodak E, Bagot M, Servitje O, Berti E, Ortiz-Romero P, Stadler R, Patsatsi A, Knobler R, Guenova E, Child F, Whittaker S, Nikolaou V, Tomasini C, Amitay I, Prag Naveh H, Ram-Wolff C, Battistella M, Alberti-Violetti S, Stranzenbach R, Gargallo V, Muniesa C, Koletsa T, Jonak C, Porkert S, Mitteldorf C, Estrach T, Combalia A, Marschalko M, Csomor J, Szepesi A, Cozzio A, Dummer R, Pimpinelli N, Grandi V, Beylot-Barry M, Pham-Ledard A, Wobser M, Geissinger E, Wehkamp U, Weichenthal M, Cowan R, Parry E, Harris J, Wachsmuth R, Turner D, Bates A, Healy E, Trautinger F, Latzka J, Yoo J, Vydianath B, Amel-Kashipaz R, Marinos L, Oikonomidi A, Stratigos A, Vignon-Pennamen MD, Battistella M, Climent F, Gonzalez-Barca E, Georgiou E, Senetta R, Zinzani P, Vakeva L, Ranki A, Busschots AM, Hauben E, Bervoets A, Woei-A-Jin FJSH, Matin R, Collins G, Weatherhead S, Frew J, Bayne M, Dunnill G, McKay P, Arumainathan A, Azurdia R, Benstead K, Twigger R, Rieger K, Brown R, Sanches JA, Miyashiro D, Akilov O, McCann S, Sahi H, Damasco FM, Querfeld C, Folkes A, Bur C, Klemke CD, Enz P, Pujol R, Quint K, Geskin L, Hong E, Evison F, Vermeer M, Cerroni L, Kempf W, Kim Y, Willemze R. The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients. Br J Dermatol 2019; 181:350-357. [PMID: 30267549 DOI: 10.1111/bjd.17258] [Citation(s) in RCA: 112] [Impact Index Per Article: 22.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/25/2018] [Indexed: 12/16/2022]
Abstract
BACKGROUND Survival in mycosis fungoides (MF) is varied and may be poor. The PROCLIPI (PROspective Cutaneous Lymphoma International Prognostic Index) study is a web-based data collection system for early-stage MF with legal data-sharing agreements permitting international collaboration in a rare cancer with complex pathology. Clinicopathological data must be 100% complete and in-built intelligence in the database system ensures accurate staging. OBJECTIVES To develop a prognostic index for MF. METHODS Predefined datasets for clinical, haematological, radiological, immunohistochemical, genotypic, treatment and quality of life are collected at first diagnosis of MF and annually to test against survival. Biobanked tissue samples are recorded within a Federated Biobank for translational studies. RESULTS In total, 430 patients were enrolled from 29 centres in 15 countries spanning five continents. Altogether, 348 were confirmed as having early-stage MF at central review. The majority had classical MF (81·6%) with a CD4 phenotype (88·2%). Folliculotropic MF was diagnosed in 17·8%. Most presented with stage I (IA: 49·4%; IB: 42·8%), but 7·8% presented with enlarged lymph nodes (stage IIA). A diagnostic delay between first symptom development and initial diagnosis was frequent [85·6%; median delay 36 months (interquartile range 12-90)]. This highlights the difficulties in accurate diagnosis, which includes lack of a singular diagnostic test for MF. CONCLUSIONS This confirmed early-stage MF cohort is being followed-up to identify prognostic factors, which may allow better management and improve survival by identifying patients at risk of disease progression. This study design is a useful model for collaboration in other rare diseases, especially where pathological diagnosis can be complex.
Collapse
Affiliation(s)
- J J Scarisbrick
- European Co-ordinating PROCLIPI Centre for PROCLIPI, University Hospitals Birmingham, Birmingham, U.K
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
- Member of the UK Cutaneous Lymphoma Group
| | - P Quaglino
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - H M Prince
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - E Papadavid
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - E Hodak
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - M Bagot
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - O Servitje
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - E Berti
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - P Ortiz-Romero
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - R Stadler
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - A Patsatsi
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - R Knobler
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - E Guenova
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - F Child
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the UK Cutaneous Lymphoma Group
| | - S Whittaker
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
- Member of the UK Cutaneous Lymphoma Group
| | - V Nikolaou
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - C Tomasini
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - I Amitay
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - H Prag Naveh
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - C Ram-Wolff
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - M Battistella
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - S Alberti-Violetti
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - R Stranzenbach
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - V Gargallo
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - C Muniesa
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - T Koletsa
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - C Jonak
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - S Porkert
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - C Mitteldorf
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - T Estrach
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - A Combalia
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - M Marschalko
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - J Csomor
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - A Szepesi
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - A Cozzio
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - R Dummer
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - N Pimpinelli
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - V Grandi
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - M Beylot-Barry
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - A Pham-Ledard
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - M Wobser
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - E Geissinger
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - U Wehkamp
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - M Weichenthal
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - R Cowan
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the UK Cutaneous Lymphoma Group
| | - E Parry
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the UK Cutaneous Lymphoma Group
| | - J Harris
- Member of the UK Cutaneous Lymphoma Group
| | - R Wachsmuth
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the UK Cutaneous Lymphoma Group
| | - D Turner
- Member of the UK Cutaneous Lymphoma Group
| | - A Bates
- Member of the UK Cutaneous Lymphoma Group
| | - E Healy
- Member of the UK Cutaneous Lymphoma Group
| | - F Trautinger
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - J Latzka
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - J Yoo
- European Co-ordinating PROCLIPI Centre for PROCLIPI, University Hospitals Birmingham, Birmingham, U.K
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - B Vydianath
- European Co-ordinating PROCLIPI Centre for PROCLIPI, University Hospitals Birmingham, Birmingham, U.K
| | - R Amel-Kashipaz
- European Co-ordinating PROCLIPI Centre for PROCLIPI, University Hospitals Birmingham, Birmingham, U.K
| | - L Marinos
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - A Oikonomidi
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - A Stratigos
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - M-D Vignon-Pennamen
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - M Battistella
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - F Climent
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - E Gonzalez-Barca
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - E Georgiou
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - R Senetta
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - P Zinzani
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - L Vakeva
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - A Ranki
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - A-M Busschots
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - E Hauben
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - A Bervoets
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - F J S H Woei-A-Jin
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - R Matin
- Member of the UK Cutaneous Lymphoma Group
| | - G Collins
- Member of the UK Cutaneous Lymphoma Group
| | | | - J Frew
- Member of the UK Cutaneous Lymphoma Group
| | - M Bayne
- Member of the UK Cutaneous Lymphoma Group
| | - G Dunnill
- Member of the UK Cutaneous Lymphoma Group
| | - P McKay
- Member of the UK Cutaneous Lymphoma Group
| | | | - R Azurdia
- Member of the UK Cutaneous Lymphoma Group
| | - K Benstead
- Member of the UK Cutaneous Lymphoma Group
| | - R Twigger
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - K Rieger
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - R Brown
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - J A Sanches
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - D Miyashiro
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - O Akilov
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - S McCann
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - H Sahi
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - F M Damasco
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - C Querfeld
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - A Folkes
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - C Bur
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - C-D Klemke
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - P Enz
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - R Pujol
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - K Quint
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - L Geskin
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - E Hong
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - F Evison
- European Co-ordinating PROCLIPI Centre for PROCLIPI, University Hospitals Birmingham, Birmingham, U.K
| | - M Vermeer
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - L Cerroni
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - W Kempf
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| | - Y Kim
- Member of the Cutaneous Lymphoma International Consortium (CLIC)
| | - R Willemze
- Member of the European Organisation of Research and Treatment of Cancer (EORTC), Cutaneous Lymphoma Task Force
| |
Collapse
|
29
|
Kostaki M, Stathopoulou A, Plaka M, Zaras A, Chatzidimitriou E, Dimitrakopoulou A, Christofidou E, Polydorou D, Stratigos A. Pazopanib induced pigmented lesions of the scrotum and the face in a patient with metastatic renal cancer. J Eur Acad Dermatol Venereol 2019; 33:e361-e362. [PMID: 31066082 DOI: 10.1111/jdv.15657] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Affiliation(s)
- M Kostaki
- First Department of Dermatology-Venereology of Medical School of Athens University, Andreas Syggros Hospital, Athens 16121, Greece
| | - A Stathopoulou
- First Department of Dermatology-Venereology of Medical School of Athens University, Andreas Syggros Hospital, Athens 16121, Greece
| | - M Plaka
- First Department of Dermatology-Venereology of Medical School of Athens University, Andreas Syggros Hospital, Athens 16121, Greece
| | - A Zaras
- First Department of Dermatology-Venereology of Medical School of Athens University, Andreas Syggros Hospital, Athens 16121, Greece
| | - E Chatzidimitriou
- First Department of Dermatology-Venereology of Medical School of Athens University, Andreas Syggros Hospital, Athens 16121, Greece
| | - A Dimitrakopoulou
- First Department of Dermatology-Venereology of Medical School of Athens University, Andreas Syggros Hospital, Athens 16121, Greece
| | - E Christofidou
- First Department of Dermatology-Venereology of Medical School of Athens University, Andreas Syggros Hospital, Athens 16121, Greece
| | - D Polydorou
- First Department of Dermatology-Venereology of Medical School of Athens University, Andreas Syggros Hospital, Athens 16121, Greece
| | - A Stratigos
- First Department of Dermatology-Venereology of Medical School of Athens University, Andreas Syggros Hospital, Athens 16121, Greece
| |
Collapse
|
30
|
Papadavid E, Kapniari E, Marinos L, Nikolaou V, Oikonomidi A, Georgakopoulos J, Stratigos A, Kouloulias V, Pappa V. Efficacy and safety of Brentuximab Vedotin in advanced cutaneous T-Cell lymphomas patients. J Eur Acad Dermatol Venereol 2019; 33:e223-e225. [PMID: 30821007 DOI: 10.1111/jdv.15409] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- E Papadavid
- National and Kapodistrian Univeristy of Athens, 2nd Department of Dermatology Venereology, Attikon General University Hospital, Athens, Greece
| | - E Kapniari
- National and Kapodistrian Univeristy of Athens, 2nd Department of Dermatology Venereology, Attikon General University Hospital, Athens, Greece
| | - L Marinos
- Hemato Pathology Department, Evaggelismos General Hospital, Athens, Greece
| | - V Nikolaou
- National and Kapodistrian University of Athens, 1st Department of Dermatology Venereology, Syggros Hospital, Athens, Greece
| | - A Oikonomidi
- National and Kapodistrian University of Athens, 1st Department of Dermatology Venereology, Syggros Hospital, Athens, Greece
| | - J Georgakopoulos
- National and Kapodistrian University of Athens, 2nd Department of Radiology, Radiology Oncology, Attikon General University Hospital, Athens, Greece
| | - A Stratigos
- National and Kapodistrian University of Athens, 1st Department of Dermatology Venereology, Syggros Hospital, Athens, Greece
| | - V Kouloulias
- National and Kapodistrian University of Athens, 2nd Department of Radiology, Radiology Oncology, Attikon General University Hospital, Athens, Greece
| | - V Pappa
- National and Kapodistrian University of Athens, 2nd Propedeutic Department, Hematology Unit, Attikon General University Hospital, Athens, Greece
| |
Collapse
|
31
|
Del Marmol V, Stratigos A, Calzavara-Pinton P, Augustin M. Sunbed use in Europe: Time for information. J Eur Acad Dermatol Venereol 2019; 33 Suppl 2:3. [PMID: 30811687 DOI: 10.1111/jdv.15310] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- V Del Marmol
- Department of Dermatology, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium
| | - A Stratigos
- First Department of Dermatology, National and Kapodistrian University of Athens, School of Medicine, Andreas Sygros Hospital, Athens, Greece
| | - P Calzavara-Pinton
- Dermatology Department, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy
| | - M Augustin
- Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany
| |
Collapse
|
32
|
Georgiou E, Nikolaou V, Papathemeli D, Pikou O, Koletsa T, Voudouri D, Sidiropoulou P, Stratigos A, Lazaridou E, Rigopoulos D, Patsatsi A. Quality of life in Greek patients with mycosis fungoides: a cross-sectional study. Eur J Cancer 2019. [DOI: 10.1016/s0959-8049(19)30621-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
33
|
Nikolaou V, Sidiropoulou P, Papanikou S, Marinos L, Voudouri D, Rigopoulos D, Chasapi V, Trafalis D, Stratigos A. Folliculotropic mycosis fungoides in the setting of nivolumab immunotherapy. Eur J Cancer 2019. [DOI: 10.1016/s0959-8049(19)30630-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
34
|
Kandolf Sekulovic L, Guo J, Agarwala S, Hauschild A, McArthur G, Cinat G, Wainstein A, Caglevic C, Lorigan P, Gogas H, Alvarez M, Duncombe R, Lebbe C, Peris K, Rutkowski P, Stratigos A, Forsea AM, De La Cruz Merino L, Kukushkina M, Dummer R, Hoeller C, Gorry C, Bastholt L, Herceg D, Neyns B, Vieira R, Arenberger P, Bylaite-Bucinskiene M, Babovic N, Banjin M, Putnik K, Todorovic V, Kirov K, Ocvirk J, Zhukavets A, Ymeri A, Stojkovski I, Garbe C. Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries. Eur J Cancer 2018; 104:201-209. [PMID: 30388700 DOI: 10.1016/j.ejca.2018.09.013] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2018] [Accepted: 09/12/2018] [Indexed: 12/19/2022]
Abstract
According to data from recent studies from Europe, a large percentage of patients have restricted access to innovative medicines for metastatic melanoma. Melanoma World Society and European Association of Dermato-oncology conducted a Web-based survey on access to first-line recommended treatments for metastatic melanoma by current guidelines (National Comprehensive Center Network, European Society for Medical Oncology [ESMO] and European Organization for Research and Treatment of Cancer/European Association of Dermato-oncology/European dermatology Forum) among melanoma experts from 27 European countries, USA, China, Australia, Argentina, Brazil, Chile and Mexico from September 1st, 2017 to July 1st, 2018. Data on licencing and reimbursement of medicines and the number of patient treated were correlated with the data on health expenditure per capita (HEPC), Mackenbach score of health policy performance, health technology assessment (HTA), ASCO and ESMO Magnitude of clinical benefit scale (ESMO MCBS) scores of clinical benefit and market price of medicines. Regression analysis for evaluation of correlation between the parameters was carried out using SPSS software. The estimated number of patients without access in surveyed countries was 13768. The recommended BRAFi + MEKi combination and anti-PD1 immunotherapy were fully reimbursed/covered in 19 of 34 (55.8%) and 17 of 34 (50%) countries, and combination anti-CTLA4+anti-PD1 in was fully covered in 6 of 34 (17.6%) countries. Median delay in reimbursement was 991 days, and it was in significant correlation with ESMO MCBS (p = 0.02), median market price (p = 0.001), HEPC and Mackenbach scores (p < 0.01). Price negotiations or managed entry agreements (MEAs) with national authorities were necessary for reimbursement. In conclusion, great discrepancy exists in metastatic melanoma treatment globally. Access to innovative medicines is in correlation with economic parameters as well as with healthcare system performance parameters. Patient-oriented drug development, market access and reimbursement pathways must be urgently found.
Collapse
Affiliation(s)
- L Kandolf Sekulovic
- Department of Dermatology, Faculty of Medicine, Military Medical Academy, Belgrade, Serbia.
| | - J Guo
- Department of Urology and Melanoma, Peking University Cancer Hospital & Institute, Beijing, PR China
| | - S Agarwala
- St. Luke's University Hospital and Temple University, Bethlehem, USA
| | - A Hauschild
- Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Kiel, Germany
| | - G McArthur
- Divisions of Research and Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia
| | - G Cinat
- Médica Oncóloga Instituto de Oncología Angel Roffo, Universidad de Buenos Aires Fundación CIDEA, Buenos Aires, Argentina
| | - A Wainstein
- Institute of Post-graduation, Faculdade de Ciências Médicas de Minas Gerais (FCM-MG) - Belo Horizonte (MG), Brazil
| | - C Caglevic
- Medical Oncology Service, Oncology Department, Clinica Alemana Santiago, Faculty of Medicine Clinica Alemana-Universidad Del Desarrollo, Santiago, Chile
| | - P Lorigan
- Institute of Cancer Sciences, University of Manchester, The Christie NHS Foundation Trust, Manchester, UK
| | - H Gogas
- 1(st)Department of Internal Medicine, Laiko Hospital and 1st Department of Dermatology-Venereology, Andreas Sygros Hospital, National and Kapodistrian University of Athens, Athens, Greece
| | - M Alvarez
- Medico en Instituto Nacional de Cancerologia, Mexico City Area, Mexico
| | - R Duncombe
- Institute of Cancer Sciences, University of Manchester, The Christie NHS Foundation Trust, Manchester, UK
| | - C Lebbe
- APHP Dermatology Department, University Paris 7 Diderot, INSERM U976, PARIS, France
| | - K Peris
- Institute of Dermatology, Catholic University of the Sacred Heart, Rome, Italy
| | - P Rutkowski
- Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland
| | - A Stratigos
- 1(st)Department of Internal Medicine, Laiko Hospital and 1st Department of Dermatology-Venereology, Andreas Sygros Hospital, National and Kapodistrian University of Athens, Athens, Greece
| | - A-M Forsea
- Carol Davila University of Medicine and Pharmacy, Elias University Hospital Bucharest, Romania
| | - L De La Cruz Merino
- Department of Clinical Oncology, Hospital Universitario Virgen Macarena, Sevilla, Spain
| | | | - R Dummer
- UniversitätsSpital Zürich-Skin Cancer Center, University Hospital, Zürich, Switzerland
| | - C Hoeller
- Department of Dermatology, Medical University of Vienna, Vienna, Austria
| | - C Gorry
- National Centre for Pharmacoeconomics, Old Stone Building, Trinity Centre for Health Sciences, St. James's Hospital, Dublin 8, Ireland
| | - L Bastholt
- Department of Oncology, Odense University Hospital, Denmark
| | - D Herceg
- Department of Oncology, University Hospital Zagreb, Croatia
| | - B Neyns
- Department of Medical Oncology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel (VUB), Brussels, Belgium
| | - R Vieira
- Department of Dermatology, Medical Faculty, University of Coimbra, Portugal
| | - P Arenberger
- Department of Dermatovenereology, Charles University 3rd Faculty of Medicine and University Hospital Kralovske Vinohrady, Prague, Czech Republic
| | | | - N Babovic
- Institute of Oncology and Radiology of Serbia, Belgrade, Serbia
| | - M Banjin
- Department of Oncology, University Hospital Sarajevo, Bosnia and Herzegovina
| | - K Putnik
- North Estonia Medical Centre, Tallinn, Estonia
| | - V Todorovic
- Clinic for Oncology and Radiotherapy, Podgorica, Montenegro
| | - K Kirov
- Clinic of Oncodermatology, National Cancer Center, Sofia, Bulgaria
| | - J Ocvirk
- Institute of Oncology Ljubljana, Ljubljana, Slovenia
| | - A Zhukavets
- Belarusian Medical Academy of Postgraduate Education (BelMAPE), Minsk, Belarus
| | - A Ymeri
- University Hospital Mother Theresa, Tirana, Albania
| | - I Stojkovski
- University Clinic of Radiotherapy and Oncology, Skopje, Macedonia
| | - C Garbe
- Centre for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany
| |
Collapse
|
35
|
Kostaki M, Polydorou D, Adamou E, Chasapi V, Antoniou C, Stratigos A. Acute localized exanthematous pustulosis due to metronidazole. J Eur Acad Dermatol Venereol 2018; 33:e109-e111. [DOI: 10.1111/jdv.15274] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- M. Kostaki
- First Department of Dermatology‐Venereology of Athens Medical School Andreas Syggros Hospital Athens Greece
| | - D. Polydorou
- First Department of Dermatology‐Venereology of Athens Medical School Andreas Syggros Hospital Athens Greece
| | - E. Adamou
- Department of Gastroenterology Evangelismos Hospital Athens Greece
| | - V. Chasapi
- First Department of Dermatology‐Venereology of Athens Medical School Andreas Syggros Hospital Athens Greece
| | - C. Antoniou
- First Department of Dermatology‐Venereology of Athens Medical School Andreas Syggros Hospital Athens Greece
| | - A. Stratigos
- First Department of Dermatology‐Venereology of Athens Medical School Andreas Syggros Hospital Athens Greece
| |
Collapse
|
36
|
Pellacani G, Gupta G, Micali G, Malvehy J, Stratigos A, Casari A, Chester J, Kaleci S, Dirschka T. Actinic Keratosis Area Severity Index (AKASI): reproducibility study and comparison with total lesion count. Br J Dermatol 2018; 179:763-764. [DOI: 10.1111/bjd.16559] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- G. Pellacani
- Department of Dermatology; University of Modena and Reggio Emilia; Italy
| | - G. Gupta
- Department of Dermatology; University Hospital Monklands; Airdrie U.K
- University of Glasgow; Glasghow U.K
| | - G. Micali
- Dermatology Clinic; University of Catania; Catania Italy
| | - J. Malvehy
- Dermatology Department; Melanoma Unit; Hospital Clínic de Barcelona; IDIBAPS; Universitat de Barcelona; Barcelona Spain
- Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER); Valencia Spain
| | - A.J. Stratigos
- First Department of Dermatology - Venereology; National and Kapodistrian University of Athens Medical School; Andreas Sygros Hospital; Athens Greece
| | - A. Casari
- Department of Dermatology; University of Modena and Reggio Emilia; Italy
| | - J. Chester
- Department of Dermatology; University of Modena and Reggio Emilia; Italy
| | - S. Kaleci
- Department of Dermatology; University of Modena and Reggio Emilia; Italy
| | - T. Dirschka
- Centroderm Clinic; Wuppertal Germany
- Faculty of Health; University Witten-Herdecke; Witten Germany
| |
Collapse
|
37
|
Stefanaki C, Soura E, Stergiopoulou A, Kontochristopoulos G, Katsarou A, Potouridou I, Rigopoulos D, Antoniou C, Stratigos A. Clinical and dermoscopic characteristics of congenital melanocytic naevi. J Eur Acad Dermatol Venereol 2018; 32:1674-1680. [DOI: 10.1111/jdv.14988] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2017] [Accepted: 03/19/2018] [Indexed: 01/30/2023]
Affiliation(s)
- C. Stefanaki
- 1st Department of Dermatology - Venereology; ‘Andreas Sygros’ University Hospital; Athens Greece
| | - E. Soura
- 1st Department of Dermatology - Venereology; ‘Andreas Sygros’ University Hospital; Athens Greece
| | - A. Stergiopoulou
- 1st Department of Dermatology - Venereology; ‘Andreas Sygros’ University Hospital; Athens Greece
| | - G. Kontochristopoulos
- State Clinic of Dermatology - Venereology; ‘Andreas Sygros’ University Hospital; Athens Greece
| | - A. Katsarou
- 1st Department of Dermatology - Venereology; ‘Andreas Sygros’ University Hospital; Athens Greece
| | - I. Potouridou
- State Clinic of Dermatology - Venereology; ‘Andreas Sygros’ University Hospital; Athens Greece
| | - D. Rigopoulos
- 1st Department of Dermatology - Venereology; ‘Andreas Sygros’ University Hospital; Athens Greece
| | - C. Antoniou
- 1st Department of Dermatology - Venereology; ‘Andreas Sygros’ University Hospital; Athens Greece
| | - A. Stratigos
- 1st Department of Dermatology - Venereology; ‘Andreas Sygros’ University Hospital; Athens Greece
| |
Collapse
|
38
|
Lear J, Migden M, Lewis K, Chang A, Guminski A, Gutzmer R, Dirix L, Combemale P, Stratigos A, Plummer R, Castro H, Yi T, Mone M, Zhou J, Trefzer U, Kaatz M, Loquai C, Kudchadkar R, Sellami D, Dummer R. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. J Eur Acad Dermatol Venereol 2018; 32:372-381. [PMID: 28846163 PMCID: PMC5873455 DOI: 10.1111/jdv.14542] [Citation(s) in RCA: 123] [Impact Index Per Article: 20.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2017] [Accepted: 08/07/2017] [Indexed: 12/19/2022]
Abstract
BACKGROUND Patients with locally advanced basal cell carcinoma (laBCC) or metastatic BCC (mBCC), two difficult-to-treat populations, have had limited treatment options. Sonidegib, a hedgehog pathway inhibitor (HPI), was approved in laBCC based on results from the BOLT trial. OBJECTIVE To evaluate long-term efficacy and safety of sonidegib in laBCC and mBCC in the BOLT 18- and 30-month analyses. METHODS BOLT (NCT01327053, ClinicalTrials.gov), a double-blind phase 2 study, enrolled patients from July 2011 until January 2013. Eligible HPI-treatment-naïve patients with laBCC not amenable to curative surgery/radiotherapy or mBCC were randomized 1 : 2 to sonidegib 200 mg (laBCC, n = 66; mBCC, n = 13) or 800 mg (laBCC, n = 128; mBCC, n = 23). Tumour response was assessed per central and investigator review. RESULTS With 30 months of follow-up, among patients treated with sonidegib 200 mg (approved dose), objective response rates were 56.1% (central) and 71.2% (investigator) in laBCC and 7.7% (central) and 23.1% (investigator) in mBCC. Tumour responses were durable as follows: median duration of response was 26.1 months (central) and 15.7 months (investigator) in laBCC and 24.0 months (central) and 18.1 months (investigator) in mBCC. Five patients with laBCC and three with mBCC in the 200-mg arm died. Median overall survival was not reached in either population; 2-year overall survival rates were 93.2% (laBCC) and 69.3% (mBCC). In laBCC, efficacy was similar regardless of aggressive or non-aggressive histology. Sonidegib 200 mg continued to have a better safety profile than 800 mg, with lower rates of grade 3/4 adverse events (43.0% vs. 64.0%) and adverse events leading to discontinuation (30.4% vs. 40.0%). CONCLUSION Sonidegib continued to demonstrate long-term efficacy and safety in these populations. These data support the use of sonidegib 200 mg per local treatment guidelines.
Collapse
Affiliation(s)
- J.T. Lear
- Manchester Academic Health Science CentreUniversity of ManchesterManchesterUK
| | - M.R. Migden
- Departments of Dermatology and Head and Neck SurgeryThe University of Texas MD Anderson Cancer CenterHoustonTXUSA
| | - K.D. Lewis
- Division of Medical OncologyUniversity of Colorado School of MedicineAuroraCOUSA
| | - A.L.S. Chang
- Stanford University School of MedicineRedwood CityCAUSA
| | - A. Guminski
- Royal North Shore HospitalSt LeonardsNSWAustralia
| | - R. Gutzmer
- Medizinische Hochschule HannoverHannoverGermany
| | - L. Dirix
- Sint‐Augustinus ZiekenhuisAntwerpBelgium
| | | | - A. Stratigos
- Andreas Syggros HospitalUniversity of AthensAthensGreece
| | - R. Plummer
- Northern Centre for Cancer CareFreeman HospitalNewcastle upon TyneUK
| | | | - T. Yi
- Novartis Pharmaceuticals CorporationEast HanoverNJUSA
| | - M. Mone
- Novartis Pharmaceuticals CorporationEast HanoverNJUSA
| | - J. Zhou
- Novartis Pharmaceuticals CorporationEast HanoverNJUSA
| | | | - M. Kaatz
- University Hospital JenaJenaGermany
| | - C. Loquai
- University Medical Center MainzMainzGermany
| | - R. Kudchadkar
- Winship Cancer Institute of Emory UniversityAtlantaGAUSA
| | - D. Sellami
- Novartis Pharmaceuticals CorporationEast HanoverNJUSA
| | - R. Dummer
- UniversitätsSpital Zürich‐Skin Cancer CenterUniversity HospitalZürichSwitzerland
| |
Collapse
|
39
|
Soura E, Dimitrakopoulou A, Christofidou E, Katoulis A, Antoniou C, Stratigos A. Patients with Spitz naevi in the Greek population: Epidemiologic, Clinical and Histopathological characteristics. J Eur Acad Dermatol Venereol 2017; 32:1128-1137. [PMID: 29150877 DOI: 10.1111/jdv.14702] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2017] [Accepted: 11/07/2017] [Indexed: 12/31/2022]
Abstract
BACKGROUND Spitz naevi may present with clinical and histopathological atypical features that do not affect patient prognosis but may become worrisome for patients ≥40 years presenting with newly appearing SN. OBJECTIVE Patient characteristics and sun behaviour patterns were investigated in correlation with age. SN characteristics and histopathological attributes were also investigated in correlation with age. METHODS Patients with histopathologically confirmed diagnosis of SN were invited for a clinical examination. Data such as skin type, number of banal/atypical naevi, sun exposure patterns and personal/family history were collected. Histopathology preparations were re-examined by two different histopathologists, and characteristics were collected based on a prespecified checklist. Patients were afterwards followed up every 6 months. RESULTS A total of 110 patients with SN were identified and assigned to three age groups. The most common area of presentation was the trunk, for the ≥40 years age group, and the limbs for the other age groups. Patients ≥40 years had a higher possibility of presenting with a naevus count ≥50 and at least one atypical naevus compared to the other age groups. Patients ≥40 years presented more commonly with a history of painful sunburn (100%) before the appearance of the SN, used less sunscreen, had higher sun exposure times and more clinical signs of solar skin damage compared to the other age groups. Finally, patients ≥40 years presented more commonly with signs of histopathological atypia such as the presence of mitoses, cellular atypia and prominent nucleolus. CONCLUSION Patients ≥40 were more likely to report a history of longer sun exposure times, of never using a sunscreen and of having a history of painful sunburn. However, the importance of this observation remains to be elucidated as these patients also presented more commonly with lesions located on non-sun-exposed areas (trunk) and higher naevus/atypical naevus counts.
Collapse
Affiliation(s)
- E Soura
- 1st University Department of Dermatology - Venereology, "Andreas Sygros" Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece
| | - A Dimitrakopoulou
- Department of Histopathology, "Andreas Sygros" Hospital, Athens, Greece
| | - E Christofidou
- Department of Histopathology, "Andreas Sygros" Hospital, Athens, Greece
| | - A Katoulis
- 2nd Department of Dermatology and Venereology, "Attikon" General University Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece
| | - C Antoniou
- 1st University Department of Dermatology - Venereology, "Andreas Sygros" Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece
| | - A Stratigos
- 1st University Department of Dermatology - Venereology, "Andreas Sygros" Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece
| |
Collapse
|
40
|
Voudouri D, Nikolaou V, Laschos K, Charpidou A, Soupos N, Triantafyllopoulou I, Panoutsopoulou I, Aravantinos G, Syrigos K, Stratigos A. Anti-PD1/PDL1 induced psoriasis. Curr Probl Cancer 2017; 41:407-412. [PMID: 29096940 DOI: 10.1016/j.currproblcancer.2017.10.003] [Citation(s) in RCA: 75] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2017] [Accepted: 10/16/2017] [Indexed: 11/28/2022]
Abstract
BACKGROUND Immune checkpoint inhibitors are novel agents approved for the treatment of late-stage malignancies. Despite its important clinical benefits, checkpoint inhibition is associated with a unique spectrum of side effects known as immune-related adverse events. Skin toxicities are the most frequent immune-related adverse events during anti-PD1 blockade therapies. Among them, rare cases of psoriasis exacerbation have been reported. METHODS We present the clinical characteristics of exacerbated psoriasis in 5 patients under anti-PD1/PDL1 therapy. RESULTS A total of 5 patients were overall included (4 males, 1 female mean age 65.8 years). Among them, 3 were diagnosed with nonsmall cell lung cancer, 1 with papillary urothelial carcinoma, and 1 with squamous cell carcinoma of the tonsil. Of all, 3 patients were treated with anti-PD1 (1 with pembrolizumab, 2 with nivolumab), whereas the remaining 2 with anti-PDL1 (durvalumab). Only 1 out of 5 patients had active psoriatic lesions at the time of treatment initiation, 2 shared a past history of psoriasis, and 1 reported a strong related family history (3/5 siblings). Four out of 5 patients experienced guttate lesions, though the most severe exacerbation was noted in the durvalumab group. Four out of 5 patients managed to continue treatment after close dermatologic monitoring, whereas 1 patient under durvalumab was forced to treatment delays owing to the severity of the skin reactions. Skin rashes appeared in all patients after the fourth cycle of immunotherapy. CONCLUSIONS Both anti-PD1 and anti-PDL1 therapies can lead to psoriasis exacerbation although more severe flares were noted in patients treated with durvalumab. Not only personal but also related family history of psoriasis are significant risk factors and need to be outlined before treatment initiation. If such related history exists, strict skin surveillance can lead to the early diagnosis and treatment of any psoriatic exacerbations that could otherwise severely affect quality of life or even compromise therapeutic protocols and final prognosis.
Collapse
Affiliation(s)
- Dimitra Voudouri
- Dermato Oncology Department, Cutaneous Toxicities Clinic, Andreas Sygros Hospital, University of Athens, Athens, Greece
| | - Vasiliki Nikolaou
- Dermato Oncology Department, Cutaneous Toxicities Clinic, Andreas Sygros Hospital, University of Athens, Athens, Greece.
| | - Konstantinos Laschos
- Second Department of Medical Oncology, Agii Anargiri Cancer Hospital, Athens, Greece
| | - Andriani Charpidou
- Third Department of Medicine, Oncology Unit, School of Medicine, Sotiria General Hospital, University of Athens, Athens, Greece
| | - Nikolaos Soupos
- Second Department of Medical Oncology, Agii Anargiri Cancer Hospital, Athens, Greece
| | - Ioanna Triantafyllopoulou
- Dermato Oncology Department, Cutaneous Toxicities Clinic, Andreas Sygros Hospital, University of Athens, Athens, Greece
| | - Ioanna Panoutsopoulou
- Dermato Oncology Department, Cutaneous Toxicities Clinic, Andreas Sygros Hospital, University of Athens, Athens, Greece
| | - Gerasimos Aravantinos
- Second Department of Medical Oncology, Agii Anargiri Cancer Hospital, Athens, Greece
| | - K Syrigos
- Third Department of Medicine, Oncology Unit, School of Medicine, Sotiria General Hospital, University of Athens, Athens, Greece
| | - A Stratigos
- Dermato Oncology Department, Cutaneous Toxicities Clinic, Andreas Sygros Hospital, University of Athens, Athens, Greece
| |
Collapse
|
41
|
Nikolaou V, Marinos L, Moustou E, Papadavid E, Economidi A, Christofidou E, Gerochristou M, Tasidou A, Economaki E, Stratigos A, Antoniou C. Psoriasis in patients with mycosis fungoides: a clinicopathological study of 25 patients. J Eur Acad Dermatol Venereol 2017; 31:1848-1852. [DOI: 10.1111/jdv.14365] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2017] [Accepted: 03/27/2017] [Indexed: 01/26/2023]
Affiliation(s)
- V. Nikolaou
- Cutaneous Lymphoma Clinic; “Andreas Sygros” Hospital for Skin Diseases; Athens Greece
| | - L. Marinos
- Hemopathology Department; “Evangelismos Hospital”; Athens Greece
| | - E. Moustou
- Cutaneous Lymphoma Clinic; “Andreas Sygros” Hospital for Skin Diseases; Athens Greece
| | - E. Papadavid
- Cutaneous Lymphoma Clinic; “Andreas Sygros” Hospital for Skin Diseases; Athens Greece
| | - A. Economidi
- Cutaneous Lymphoma Clinic; “Andreas Sygros” Hospital for Skin Diseases; Athens Greece
| | - E. Christofidou
- Pathology Department; “Andreas Sygros” Hospital for Skin Diseases; Athens Greece
| | - M. Gerochristou
- Cutaneous Lymphoma Clinic; “Andreas Sygros” Hospital for Skin Diseases; Athens Greece
| | - A. Tasidou
- Hemopathology Department; “Evangelismos Hospital”; Athens Greece
| | - E. Economaki
- Hemopathology Department; “Evangelismos Hospital”; Athens Greece
| | - A. Stratigos
- Cutaneous Lymphoma Clinic; “Andreas Sygros” Hospital for Skin Diseases; Athens Greece
| | - C. Antoniou
- Cutaneous Lymphoma Clinic; “Andreas Sygros” Hospital for Skin Diseases; Athens Greece
| |
Collapse
|
42
|
Affiliation(s)
- C. Stefanaki
- Department of Dermatology-Venereology; National and Kapodestrian University of Athens School of Medicine; Andreas Sygros Hospital; Athens Greece
| | - A. Stratigos
- Department of Dermatology-Venereology; National and Kapodestrian University of Athens School of Medicine; Andreas Sygros Hospital; Athens Greece
| |
Collapse
|
43
|
Stefanaki C, Chardalias L, Soura E, Katsarou A, Stratigos A. Paediatric melanoma. J Eur Acad Dermatol Venereol 2017; 31:1604-1615. [PMID: 28449284 DOI: 10.1111/jdv.14299] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2016] [Accepted: 04/03/2017] [Indexed: 02/06/2023]
Abstract
Paediatric melanoma, although rare, is the most common skin cancer in children. Our current knowledge on paediatric melanoma incidence trends is expanding, as several studies have addressed this issue with conflicting results. Known risk factors for paediatric melanoma include family history of melanoma, a previous history of malignancy, large congenital nevi, numerous melanocytic nevi, sunburns, increased UV exposure and a sun-sensitive phenotype. In younger children, melanoma more often presents with atypical features, such as a changing, amelanotic or uniformly coloured, often bleeding lesion, not fulfilling in most cases the conventional ABCDE criteria. The major differential diagnoses are melanocytic nevi, proliferative nodules in congenital nevi and atypical Spitz tumours. Moreover, in the younger age group non-Caucasian children are over-represented, tumours tend to be thicker and lymph nodes are often involved. Despite the frequent diagnosis at an advanced stage, the overall survival is fair in paediatric melanoma. Specific guidelines for management of melanoma in children do not exist, and most often the disease is treated similarly to melanoma in adults.
Collapse
Affiliation(s)
- C Stefanaki
- University Department of Dermatology - Venereology, "Andreas Sygros" Hospital, Athens, Greece
| | - L Chardalias
- University Department of Dermatology - Venereology, "Andreas Sygros" Hospital, Athens, Greece
| | - E Soura
- University Department of Dermatology - Venereology, "Andreas Sygros" Hospital, Athens, Greece
| | - A Katsarou
- University Department of Dermatology - Venereology, "Andreas Sygros" Hospital, Athens, Greece
| | - A Stratigos
- University Department of Dermatology - Venereology, "Andreas Sygros" Hospital, Athens, Greece
| |
Collapse
|
44
|
Nikolaou V, Papadavid E, Patsatsi A, Siakantaris M, Economidi A, Marinos L, Koletsa T, Georgiou E, Pappa V, Stratigos A, Antoniou C. Prognostic indicators for mycosis fungoides in a Greek population. Br J Dermatol 2017; 176:1321-1330. [DOI: 10.1111/bjd.15000] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/20/2016] [Indexed: 12/12/2022]
Affiliation(s)
- V. Nikolaou
- National and Kapodistrian University of Athens; Medical School; Athens Greece
| | - E. Papadavid
- National and Kapodistrian University of Athens; Medical School; Athens Greece
| | - A. Patsatsi
- Aristotle University School of Medicine; Thessaloniki Greece
| | - M. Siakantaris
- National and Kapodistrian University of Athens; Medical School; Athens Greece
| | - A. Economidi
- National and Kapodistrian University of Athens; Medical School; Athens Greece
| | - L. Marinos
- Department of Hemopathology; Evangelismos Hospital; Athens Greece
| | - T. Koletsa
- Aristotle University School of Medicine; Thessaloniki Greece
| | - E. Georgiou
- Aristotle University School of Medicine; Thessaloniki Greece
| | - V. Pappa
- National and Kapodistrian University of Athens; Medical School; Athens Greece
| | - A. Stratigos
- National and Kapodistrian University of Athens; Medical School; Athens Greece
| | - C. Antoniou
- National and Kapodistrian University of Athens; Medical School; Athens Greece
| |
Collapse
|
45
|
Dessinioti C, Plaka M, Zisimou C, Christofidou E, Antoniou C, Stratigos A. Advanced squamous cell carcinoma of the axillae mimicking hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2017; 31:e421-e423. [DOI: 10.1111/jdv.14235] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- C. Dessinioti
- Hidradenitis Clinic; Department of Dermatology; Andreas Syggros Hospital; University of Athens; Athens Greece
| | - M. Plaka
- Dermato-Oncology Unit; Department of Dermatology; Andreas Syggros Hospital; University of Athens; Athens Greece
| | - C. Zisimou
- Hidradenitis Clinic; Department of Dermatology; Andreas Syggros Hospital; University of Athens; Athens Greece
| | - E. Christofidou
- Histopathology Department; Andreas Syggros Hospital; Athens Greece
| | - C. Antoniou
- Hidradenitis Clinic; Department of Dermatology; Andreas Syggros Hospital; University of Athens; Athens Greece
| | - A.J. Stratigos
- Dermato-Oncology Unit; Department of Dermatology; Andreas Syggros Hospital; University of Athens; Athens Greece
| |
Collapse
|
46
|
Soura E, Plaka M, Stefanaki C, Chasapi V, Christofidou E, Antoniou C, Stratigos A. Characteristics of Spitz nevi, Atypical Spitz nevi and Melanomas in patients younger than 20 years. J Eur Acad Dermatol Venereol 2017; 31:e384-e385. [PMID: 28295655 DOI: 10.1111/jdv.14208] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Affiliation(s)
- E Soura
- 1st University Department of Dermatology - Venereology, 'Andreas Sygros' Hospital, Athens, Greece
| | - M Plaka
- 1st University Department of Dermatology - Venereology, 'Andreas Sygros' Hospital, Athens, Greece
| | - C Stefanaki
- 1st University Department of Dermatology - Venereology, 'Andreas Sygros' Hospital, Athens, Greece
| | - V Chasapi
- State Clinic of Dermatology - Venereology, 'Andreas Sygros' Hospital, Athens, Greece
| | - E Christofidou
- Histopathology Department of 'Andreas Sygros' Hospital, Athens, Greece
| | - C Antoniou
- 1st University Department of Dermatology - Venereology, 'Andreas Sygros' Hospital, Athens, Greece
| | - A Stratigos
- 1st University Department of Dermatology - Venereology, 'Andreas Sygros' Hospital, Athens, Greece
| |
Collapse
|
47
|
Dimonitsas E, Charitos G, Fragia-Tsivou K, Dritsakos K, Fostira F, Christodoulaki E, Kentepozidis N, Stefanaki I, Stratigos A, Kapiris I. Synchronous malignant tumors of different genesis in axillary lymph nodes. Breast 2017. [DOI: 10.1016/s0960-9776(17)30221-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
48
|
Langton AK, Tsoureli-Nikita E, Griffiths CEM, Katsambas A, Antoniou C, Stratigos A, Sherratt MJ, Watson REB. Lysyl oxidase activity in human skin is increased by chronic ultraviolet radiation exposure and smoking. Br J Dermatol 2017; 176:1376-1378. [PMID: 27514484 DOI: 10.1111/bjd.14959] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- A K Langton
- Centre for Dermatology Research, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, U.K.,The Dermatology Centre, Salford Royal NHS Foundation Trust, Salford, U.K
| | - E Tsoureli-Nikita
- Centre for Dermatology Research, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, U.K.,The Dermatology Centre, Salford Royal NHS Foundation Trust, Salford, U.K.,Department of Dermatology, Andreas Sygros Hospital for Skin and Venereal Diseases, Athens, Greece
| | - C E M Griffiths
- Centre for Dermatology Research, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, U.K.,The Dermatology Centre, Salford Royal NHS Foundation Trust, Salford, U.K
| | - A Katsambas
- Department of Dermatology, Andreas Sygros Hospital for Skin and Venereal Diseases, Athens, Greece
| | - C Antoniou
- Department of Dermatology, Andreas Sygros Hospital for Skin and Venereal Diseases, Athens, Greece
| | - A Stratigos
- Department of Dermatology, Andreas Sygros Hospital for Skin and Venereal Diseases, Athens, Greece
| | - M J Sherratt
- Cell Matrix Biology and Regenerative Medicine, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, U.K
| | - R E B Watson
- Centre for Dermatology Research, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, U.K.,The Dermatology Centre, Salford Royal NHS Foundation Trust, Salford, U.K
| |
Collapse
|
49
|
Soura E, Chasapi V, Stratigos A. Programmed cell death protein-1 inhibitors for immunotherapy of advanced nonmelanoma skin cancer: showing early promise. Br J Dermatol 2016; 175:1150-1151. [DOI: 10.1111/bjd.14905] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- E. Soura
- Department of Dermatology; Andreas Sygros Hospital; University of Athens; Athens Greece
| | - V. Chasapi
- Department of Dermatology; Andreas Sygros Hospital; University of Athens; Athens Greece
| | - A.J. Stratigos
- Department of Dermatology; Andreas Sygros Hospital; University of Athens; Athens Greece
| |
Collapse
|
50
|
Dessinioti C, Zisimou C, Tzanetakou V, Stratigos A, Antoniou C. Oral clindamycin and rifampicin combination therapy for hidradenitis suppurativa: a prospective study and 1-year follow-up. Clin Exp Dermatol 2016; 41:852-857. [PMID: 27753139 DOI: 10.1111/ced.12933] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/22/2016] [Indexed: 12/01/2022]
Abstract
BACKGROUND Limited data exist on the use of systemic antibiotic treatment for hidradenitis supportive (HS). AIM To investigate the effectiveness, safety and relapse rate of HS treated with a combination of daily oral clindamycin and rifampicin. METHODS This was a prospective, hospital-based study of oral clindamycin 600 mg and rifampicin 600 mg daily for 12 weeks for treatment of HS. Patients were followed up for 1 year to monitor for relapse. RESULTS In total, 26 patients with HS received oral clindamycin and rifampicin. Most were overweight or obese (73%), and most were smokers (88%). After 12 weeks, clinical response was noted in 19 patients (73%). Response was associated only with female sex (P = 0.02), and not with body mass index, Hurley stage or lesion location. Eight patients (31%) experienced adverse events. At the 1-year follow-up, there was sustained efficacy in 7 (41%) patients, while 10 (59%) had disease relapse after a mean time of 4.2 months. CONCLUSIONS Oral clindamycin with oral rifampicin for 12 weeks is an effective and tolerable regimen for HS.
Collapse
Affiliation(s)
- C Dessinioti
- First Department of Dermatology, Andreas Sygros Hospital, University of Athens, Athens, Greece
| | - C Zisimou
- First Department of Dermatology, Andreas Sygros Hospital, University of Athens, Athens, Greece
| | - V Tzanetakou
- First Department of Dermatology, Andreas Sygros Hospital, University of Athens, Athens, Greece
| | - A Stratigos
- First Department of Dermatology, Andreas Sygros Hospital, University of Athens, Athens, Greece
| | - C Antoniou
- First Department of Dermatology, Andreas Sygros Hospital, University of Athens, Athens, Greece
| |
Collapse
|